<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias - Foong, WC - 2023 | Cochrane Library</title> <meta content="Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias - Foong, WC - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013767.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias - Foong, WC - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013767.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013767.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias" name="citation_title"/> <meta content="Wai Cheng Foong" name="citation_author"/> <meta content="RCSI &amp; UCD Malaysia Campus (formerly Penang Medical College)" name="citation_author_institution"/> <meta content="wcfoong@rcsiucd.edu.my" name="citation_author_email"/> <meta content="C Khai Loh" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Jacqueline J Ho" name="citation_author"/> <meta content="RCSI &amp; UCD Malaysia Campus (formerly Penang Medical College)" name="citation_author_institution"/> <meta content="Doris SC Lau" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD013767.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/01/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013767.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013767.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013767.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*beta-Thalassemia [therapy]; Blood Transfusion; Fetal Hemoglobin; Hydroxyurea; Resveratrol" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013767.pub2&amp;doi=10.1002/14651858.CD013767.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013767\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013767\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013767.pub2",title:"Foetal haemoglobin inducers for reducing blood transfusion in non\\u2010transfusion\\u2010dependent beta\\u2010thalassaemias",firstPublishedDate:"Jan 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013767.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013767.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013767.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013767.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013767.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013767.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013767.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013767.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013767.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013767.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1444 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013767.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/appendices#CD013767-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/supinfo/CD013767StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/supinfo/CD013767StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#CD013767-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Wai Cheng Foong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#CD013767-cr-0005">C Khai Loh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#CD013767-cr-0006">Jacqueline J Ho</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information#CD013767-cr-0007">Doris SC Lau</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information/en#CD013767-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 January 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013767.pub2">https://doi.org/10.1002/14651858.CD013767.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013767-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013767-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013767-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013767-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013767-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013767-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013767-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013767-abs-0001" lang="en"> <section id="CD013767-sec-0001"> <h3 class="title" id="CD013767-sec-0001">Background</h3> <p>Non‐transfusion‐dependent β‐thalassaemia (NTDβT) is a subset of inherited haemoglobin disorders characterised by reduced production of the β‐globin chain of haemoglobin leading to anaemia of varying severity. Although blood transfusion is not a necessity for survival, it may be required to prevent complications of chronic anaemia, such as impaired growth and hypercoagulability. People with NTDβT also experience iron overload due to increased iron absorption from food sources which becomes more pronounced in those requiring blood transfusion. </p> <p>People with a higher foetal haemoglobin (HbF) level have been found to require fewer blood transfusions, thus leading to the emergence of treatments that could increase its level. HbF inducers stimulate HbF production without altering any gene structures. Evidence for the possible benefits and harms of these inducers is important for making an informed decision on their use. </p> </section> <section id="CD013767-sec-0002"> <h3 class="title" id="CD013767-sec-0002">Objectives</h3> <p>To compare the effectiveness and safety of the following for reducing blood transfusion for people with NTDβT: </p> <p>1. HbF inducers versus usual care or placebo;</p> <p>2. single HbF inducer with another HbF inducer, and single dose with another dose; and </p> <p>3. combination of HbF inducers versus usual care or placebo, or single HbF inducer.</p> </section> <section id="CD013767-sec-0003"> <h3 class="title" id="CD013767-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 21 August 2022. </p> </section> <section id="CD013767-sec-0004"> <h3 class="title" id="CD013767-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) or quasi‐RCTs comparing single HbF inducer with placebo or usual care, with another single HbF inducer or with a combination of HbF inducers; or comparing different doses of the same HbF inducer. </p> </section> <section id="CD013767-sec-0005"> <h3 class="title" id="CD013767-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were blood transfusion and haemoglobin levels. Our secondary outcomes were HbF levels, the long‐term sequelae of NTDβT, quality of life and adverse events. </p> </section> <section id="CD013767-sec-0006"> <h3 class="title" id="CD013767-sec-0006">Main results</h3> <p>We included seven RCTs involving 291 people with NTDβT, aged two to 49 years, from five countries. We reported 10 comparisons using eight different HbF inducers (four pharmacological and four natural): three RCTs compared a single HbF inducer to placebo and seven to another HbF inducer. The duration of the intervention lasted from 56 days to six months. Most studies did not adequately report the randomisation procedures or whether and how blinding was achieved. </p> <p><b>HbF inducer against placebo or usual care</b> </p> <p>Three HbF inducers, HQK‐1001, Radix Astragali or a 3‐in‐1 combined natural preparation (CNP), were compared with a placebo. None of the comparisons reported the frequency of blood transfusion. We are uncertain whether Radix Astragali and CNP increase haemoglobin at three months (mean difference (MD) 1.33 g/dL, 95% confidence interval (CI) 0.54 to 2.11; 1 study, 2 interventions, 35 participants; very low‐certainty evidence). We are uncertain whether Radix Astragali and CNP have any effect on HbF (MD 12%, 95% CI −0.74% to 24.75%; 1 study, 2 interventions, 35 participants; very low‐certainty evidence). Only medians on haemoglobin and HbF levels were reported for HQK‐1001. </p> <p>Adverse effects reported for HQK‐1001 were nausea, vomiting, dizziness and suprapubic pain. There were no prespecified adverse effects for Radix Astragali and CNP. </p> <p><b>HbF inducer versus another HbF inducer</b> </p> <p>Four studies compared a single inducer with another over three to six months. Comparisons included hydroxyurea versus resveratrol, hydroxyurea versus thalidomide, hydroxyurea versus decitabine and Radix Astragali versus CNP. No study reported our prespecified outcomes on blood transfusion. Haemoglobin and HbF were reported for the comparison Radix Astragali versus CNP, but we are uncertain whether there were any differences (1 study, 24 participants; low‐certainty evidence). </p> <p><b>Different doses of the same HbF inducer</b> </p> <p>Two studies compared two different types of HbF inducers at different doses over two to six months. Comparisons included hydroxyurea 20 mg/kg/day versus 10 mg/kg/day and HQK‐1001 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day and 40 mg/kg/day. Blood transfusion, as prespecified, was not reported. In one study (61 participants) we are uncertain whether the lower levels of both haemoglobin and HbF at 24 weeks were due to the higher dose of hydroxyurea (haemoglobin: MD −2.39 g/dL, 95% CI −2.80 to −1.98; very low‐certainty evidence; HbF: MD −10.20%, 95% CI −16.28% to −4.12%; very low‐certainty evidence). The study of the four different doses of HQK‐1001 did not report results for either haemoglobin or HbF. We are not certain if major adverse effects may be more common with higher hydroxyurea doses (neutropenia: risk ratio (RR) 9.93, 95% CI 1.34 to 73.97; thrombocytopenia: RR 3.68, 95% CI 1.12 to 12.07; very low‐certainty evidence). Taking HQK‐1001 20 mg/kg/day may result in the fewest adverse effects. </p> <p><b>A combination of HbF inducers versus a single HbF inducer</b> </p> <p>Two studies compared three combinations of two inducers with a single inducer over six months: hydroxyurea plus resveratrol versus resveratrol or hydroxyurea alone, and hydroxyurea plus l‐carnitine versus hydroxyurea alone. Blood transfusion was not reported. </p> <p>Hydroxyurea plus resveratrol may reduce haemoglobin compared with either resveratrol or hydroxyurea alone (MD −0.74 g/dL, 95% CI −1.45 to −0.03; 1 study, 54 participants; low‐certainty evidence). We are not certain whether the gastrointestinal disturbances, headache and malaise more commonly reported with hydroxyurea plus resveratrol than resveratrol alone were due to the interventions. </p> <p>We are uncertain whether hydroxyurea plus l‐carnitine compared with hydroxyurea alone may increase mean haemoglobin, and reduce pulmonary hypertension (1 study, 60 participants; very low‐certainty evidence). Adverse events were reported but not in the intervention group. </p> <p>None of the comparisons reported the outcome of HbF.</p> </section> <section id="CD013767-sec-0007"> <h3 class="title" id="CD013767-sec-0007">Authors' conclusions</h3> <p>We are uncertain whether any of the eight HbF inducers in this review have a beneficial effect on people with NTDβT. For each of these HbF inducers, we found only one or at the most two small studies. There is no information on whether any of these HbF inducers have an effect on our primary outcome, blood transfusion. For the second primary outcome, haemoglobin, there may be small differences between intervention groups, but these may not be clinically meaningful and are of low‐ to very low‐certainty evidence. Data on adverse effects and optimal doses are limited. Five studies are awaiting classification, but none are ongoing. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013767-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013767-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013767-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013767-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013767-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013767-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013767-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD013767-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013767-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013767-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013767-abs-0002" lang="en"> <h3>Medicines to increase foetal haemoglobin levels and reduce the need for blood transfusion in people with non‐transfusion‐dependent thalassaemia </h3> <p><b>Review question</b> </p> <p>Do medicines that increase foetal haemoglobin (HbF) levels in people with non‐transfusion‐dependent β‐thalassaemia (NTDβT) reduce their need for blood transfusion? </p> <p><b>What is thalassaemia?</b> </p> <p>Thalassaemia is a genetic (inherited) blood disorder that causes defects in adult haemoglobin (the oxygen carrying component of red blood cells) leading to destruction of the red blood cells and anaemia with different degrees of severity. Persistent anaemia can affect general health and reduce quality of life. People with NTDβT may require periodic blood transfusion to replace the red blood cells and this could lead to excess iron being deposited in various organs in the body, affecting their function. </p> <p>People with NTDβT have higher levels of HbF (the main form of haemoglobin found during the development of a baby before birth) which persists after birth. The amount of HbF that persists varies and people with a higher HbF level require less frequent blood transfusions. </p> <p><b>What are HbF inducers?</b> </p> <p>HbF inducers are substances which increase HbF levels without alteration to the gene. They may reduce the need for blood transfusion in people with NTDβT. However, it is not known which HbF inducers are effective and safe, and if so, what the optimal dose is and at what age treatment should be started. </p> <p><b>What did we do?</b> </p> <p>We searched medical databases for studies comparing single HbF inducer with placebo (dummy treatment) or usual care, with another inducer or with a combination of inducers; or comparing different doses for a same inducer. </p> <p><b>What did we find?</b> </p> <p>We found seven very small randomised controlled trials (where people taking part in the trial had equal chances of being in the treatment or the control group), involving 291 people with NTDβT, aged between two and 49 years, from five countries. These studies varied widely in the type of HbF inducers investigated and their comparison, the doses and how outcomes were reported. The duration of the trials ranged from two to six months. The inducers used include hydroxyurea, decitabine, HQK‐1001, thalidomide, Radix Astragali, resveratrol, l‐carnitine and combined natural preparation (CNP). </p> <p><b>Main results</b> </p> <p>None of the studies reported our main outcome of changes to the frequency of blood transfusion. </p> <p>All inducers may have caused a small increase in haemoglobin and HbF when compared to placebo, but we are very uncertain about this. </p> <p>Four studies compared a single HbF inducer against another, for three to six months. There were changes to haemoglobin and HbF, but we cannot be certain if a single HbF inducer or a combination of HbF inducers would work better than another. </p> <p>Two studies, each compared a different dose of the same inducer. Lower doses of hydroxyurea appeared to increase haemoglobin and HbF levels more than the higher doses, but we are very uncertain. The other study used four different doses of HQK‐1001 but did not actually look for a difference in the effect of these four different doses on haemoglobin or HbF. </p> <p>Two studies compared a combination of two HbF inducers with a single HbF inducer for six months. We are very uncertain whether the combination or a single inducer improves haemoglobin. </p> <p>None of the studies reported whether HbF inducers have any effect on quality of life.</p> <p>Adverse (unwanted) drug effects were reported for each HbF inducer, but there was little information available to guide us on the safety of these substances. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The main reason we are very uncertain about the effects of HbF inducers are because the studies were all very small and had weaknesses in their design. None of the studies lasted long enough to provide meaningful information for many of the outcomes we measured. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current to 21 August 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013767-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013767-sec-0132"></div> <h3 class="title" id="CD013767-sec-0133">Implications for practice</h3> <section id="CD013767-sec-0133"> <p>We are uncertain whether any of the eight foetal haemoglobin (HbF) inducers in this review have a beneficial effect on people with non‐transfusion‐dependent β‐thalassaemia (NTDβT). For each of these HbF inducers, we found only one or two small studies. There is no information on whether any of these HbF inducers have an effect on our primary outcome, blood transfusion. For the second primary outcome, haemoglobin, there may be small differences between intervention groups, but these may not be clinically meaningful and are of very low‐certainty evidence. Although we found HbF inducers may increase HbF, the evidence is very uncertain. There is no information about which single inducer might be more beneficial than another, or whether a combination of inducers might be better than a single inducer. We are very uncertain about the potential adverse effects of each inducer. Although evidence was very low‐certainty, at higher doses increased adverse effects were seen. Five studies are awaiting classification which may provide more information if we are able to include these in an update of the review. More evidence is needed for recommendation of the use of HbF inducers, be them alone or in combination, to reduce the need for blood transfusion through a rise in haemoglobin or HbF levels. There are insufficient data on which to make a treatment of choice. </p> </section> <h3 class="title" id="CD013767-sec-0134">Implications for research</h3> <section id="CD013767-sec-0134"> <p>This review suggests several areas where further research is needed.</p> <p>This Cochrane Review has shown that more studies are needed for all the currently studied HbF inducers. In particular, studies comparing an HbF inducer with a placebo are needed. Hydroxyurea appears to have been introduced into clinical practice for the treatment of NTDβT without adequate evaluation. No studies have compared hydroxyurea with a placebo. Therefore, there is an urgent need for large well‐designed randomised controlled trials comparing HbF inducers with placebo or usual care in people with NTDβT and, wherever possible, placebo‐controlled studies are preferable. </p> <p>Since placebos such as teas or soups may be used in future studies, and these potentially could have some activity of their own, future studies need to adequately describe the nature of any placebo used, including whether participants are able to distinguish it from the intervention. </p> <p>The primary outcome in future studies should be blood transfusion. Studies should be of sufficient duration to determine this outcome and criteria for blood transfusion need to be well‐defined. Since there is some evidence that the effects of HbF inducers might not be sustained, studies of sufficient duration to detect these are needed, perhaps up to two years, and outcomes might need to be measured at several prespecified time points prior to this. Longer study durations are also needed to detect changes in quality of life, changes to the long‐term sequelae of chronic anaemia, as well as enabling further monitoring for any adverse drug events and the complications of both the disease and blood transfusion. </p> <p>Studies comparing a single HbF inducer or a combination of inducers with another HbF inducer should only proceed once the effectiveness of the inducer has been determined in placebo‐controlled studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013767-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013767-sec-0008"></div> <div class="table" id="CD013767-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with usual care or placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Single HbF inducer at any dose or duration compared with usual care or placebo for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in Thailand, Lebanon and China<br/><b>Intervention:</b> single HbF inducer <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level (g/dL) at 3 months was <b>7.3 (SD 1.1) g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.33 g/dL higher</b><br/>(0.54 higher to 2.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT, 2 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The meta‐analysis include Radix Astragali and CNP, but not HQK‐1001. For HQK‐1001, there was no difference in median haemoglobin for any of the 4 doses compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF (%)</b> </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF level (%) at 3 months was <b>54% (SD 17%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 12% higher</b><br/>(−0.74% lower to 24.75% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT, 2 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The meta‐analysis include Radix Astragali and CNP, but not HQK‐1001.</p> <p>Of the 4 different doses of HQK‐1001 (21 participants), there was an increase in median HbF only with the 20 mg/kg dose when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>HQK‐1001 </p> <p>The reported adverse events for each dose of HQK‐1001 were URTI, headache, fever, fatigue, nausea, dizziness, palpitations, suprapubic pain, gastritis, gastroenteritis and severe URTI. The 20 mg/kg/day dose was reported as the dose with the least adverse events – on this dose, 2/9 participants reported URTI, 3/9 reported headache, 1/9 reported suprapubic pain, 2/9 reported nausea and 2/9 reported dizziness, and were free from other adverse effects. However, these events were too few to determine whether higher doses were associated with more or fewer adverse effects or whether there were more adverse effects in the HbF inducer or placebo groups. </p> <p>Radix Astragali </p> <p>No adverse events were reported; no deranged blood counts (white blood cells, neutrophils, platelets), liver (GGT, ALT, AST) and renal (BUN, creatinine) blood profiles. </p> <p>CNP </p> <p>No adverse events were reported; no deranged blood counts (white blood cells, neutrophils, platelets), liver (GGT, ALT, AST) and renal (BUN, creatinine) blood profiles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(2 RCTs, 3 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ALT:</b> alanine transaminase; <b>AST:</b> aspartate aminotransferase; <b>BUN:</b> blood urea nitrogen; <b>CI:</b> confidence interval; <b>CNP:</b> combined natural preparation; <b>GGT:</b> gamma‐glutamyl transferase; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation; <b>URTI:</b> upper respiratory tract infection. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for indirectness because the follow‐up duration was short and insufficient to see changes.<br/><sup>b</sup>Downgraded two levels for imprecision because of very small information size well below the optimal information size.<br/><sup>c</sup>Downgraded two levels for imprecision because optimal information size was not achieved and there were wide CIs that included both appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013767-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Overview of adverse events reported in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HbF inducer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects prespecified in study method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects reported<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Hydroxyurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation on blood investigation (complete blood count, kidney and liver function tests). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg/day</p> <p> <ol id="CD013767-list-0001"> <li> <p>Severe neutropenia (9/29 participants)</p> </li> <li> <p>Thrombocytopenia (10/29 participants)</p> </li> <li> <p>Raised ALT and AST (5/29 participants)</p> </li> <li> <p>Gastrointestinal adverse effects (9/29 participants)</p> </li> </ol> </p> <p>10 mg/kg/day</p> <p> <ol id="CD013767-list-0002"> <li> <p>Severe neutropenia (1/32 participants)</p> </li> <li> <p>Thrombocytopenia (3/32 participants)</p> </li> <li> <p>Raised ALT and AST (2/32 participants)</p> </li> <li> <p>Gastrointestinal adverse effects (3/32 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation on blood investigation (complete blood count, serum ferritin levels, kidney and liver function tests, and fasting blood sugar), and history and physical examination of any occurrence of adverse events. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding (1/18 participants). </p> <p>Headache and malaise were also reported for some participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation of clinical complaints and physical findings.</p> <p>Biochemical parameters and blood counts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting (6 participants), headache (1 participant) and abdominal discomfort (1 participant) without specification to which group the participants were randomised into. </p> <p>No changes to the biochemical parameters and blood counts.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability and safety.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild gastrointestinal upset (number of participants not reported).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, cytopenia, infection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0003"> <li> <p>Respiratory tract infection (10/15 participants)</p> </li> <li> <p>Neurological (1/15 participants)</p> </li> <li> <p>Fever (2/15 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQK‐1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, coagulation profile, blood counts, urinalysis and ECG.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>URTI</p> <p> <ol id="CD013767-list-0004"> <li> <p>10 mg/kg/day: 5/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 1/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 3/8 participants</p> </li> </ol> </p> <p>Headache</p> <p> <ol id="CD013767-list-0005"> <li> <p>10 mg/kg/day: 5/8 participants</p> </li> <li> <p>20 mg/kg/day: 3/9 participants</p> </li> <li> <p>30 mg/kg/day: 2/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 2/8 participants</p> </li> </ol> </p> <p>Fever</p> <p> <ol id="CD013767-list-0006"> <li> <p>10 mg/kg/day: 3/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 2/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 2/8 participants</p> </li> </ol> </p> <p>Fatigue</p> <p> <ol id="CD013767-list-0007"> <li> <p>10 mg/kg/day: 1/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 4/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> <p>Nausea</p> <p> <ol id="CD013767-list-0008"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Dizziness</p> <p> <ol id="CD013767-list-0009"> <li> <p>10 mg/kg/day: 2/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Palpitations</p> <p> <ol id="CD013767-list-0010"> <li> <p>10 mg/kg/day: 1/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Suprapubic pain</p> <p> <ol id="CD013767-list-0011"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 1/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Gastritis</p> <p> <ol id="CD013767-list-0012"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 1/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Gastroenteritis</p> <p> <ol id="CD013767-list-0013"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> <p>Severe URTI</p> <p> <ol id="CD013767-list-0014"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thalidomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability and safety.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence and headache</p> <p>Number of participants with events not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, cytopenia, infection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0015"> <li> <p>Respiratory tract infection (2/15 participants)</p> </li> <li> <p>Neurological (0/15 participants)</p> </li> <li> <p>Fever (0/15 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali (黄芪) in a tea bag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood counts (WBC, neutrophils, platelets), liver function (GGT, AST, ALT), renal profile (BUN, creatinine). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None occurred.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CNP in a tea bag.</p> <p>CNP: combination of Radix Astragali (黄芪), <i>Codonopsis pilosula</i> (党参) and tortoise plastron (龟板) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evaluation on blood investigation (complete blood count, serum ferritin levels, kidney and liver function tests, and fasting blood sugar), and history and physical examination of any occurrence of adverse events. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea and gastrointestinal bleeding (5/16 participants). </p> <p>Headache and malaise were also reported for some of the participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea plus resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding (5/20 participants) </p> <p>Headache and malaise were also reported for some of the participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea plus l‐carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation of clinical complaints and physical findings.</p> <p>Biochemical parameters and blood counts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting (6 participants), headache (1 participant) and abdominal discomfort (1 participant) without specification to which group the participants were randomised into. </p> <p>No changes to the biochemical parameters and blood counts.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>'None occurred' means that adverse effects were specifically looked for, but none were identified.<br/>ALT: alanine transaminase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CNP: combination natural preparation; ECG: electrocardiogram; GGT: gamma‐glutamyl transferase; URTI: upper respiratory tract infection; WBC: white blood cell count. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013767-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with another foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Single HbF inducer at any dose or duration compared with another HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in Iran, India and China<br/><b>Intervention:</b> single HbF inducer <br/><b>Comparison:</b> another single HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with single HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with another single HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> (transfused volume/year) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>None of the studies reported this outcome using the scale transfused volume/year.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported frequency of transfusion (30 participants, 15 per arm) as mean number of units of blood/participant/year. SDs were not reported. The hydroxyurea group needed a mean of 3 units/participant/year of blood volume (range 1 to 6), while 0 participants in the thalidomide group needed any units of blood. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Hydroxyurea lowered mean haemoglobin compared to resveratrol by MD 0.30 g/dL (95% CI −1.14 to 0.54). </p> <p>Radix Astragali lowered mean haemoglobin compared to CNP by MD 0.50 g/dL (95% CI −1.38 to 0.38). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (4 RCTs, 4 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0016"> <li> <p>Comparisons include: hydroxyurea vs resveratrol; hydroxyurea vs thalidomide; hydroxyurea vs decitabine; and Radix Astragali vs CNP. </p> </li> </ol> </p> <p>The study comparing hydroxyurea vs thalidomide did not report this outcome and the study comparing hydroxyurea vs decitabine reported this outcome as peak median haemoglobin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF</b> (%) </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between thalidomide and hydroxyurea, MD 3.50% (95% CI −1.41% to 8.41%). </p> <p>Radix Astragali increased the mean HbF levels compared to natural combination preparation by 5.00% (95% CI −11.44% to 21.44%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (3 RCTs, 3 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparisons include hydroxyurea vs thalidomide; hydroxyurea vs decitabine; and Radix Astragali vs CNP. </p> <p>The study comparing hydroxyurea vs decitabine reported this outcome but did not provide sufficient information to compare the 2 groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Hydroxyurea </p> <p> <ol id="CD013767-list-0017"> <li> <p>mild gastrointestinal upset (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>) </p> </li> <li> <p>respiratory tract infection (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> <li> <p>neurological problems (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> <li> <p>fever (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> </ol> </p> <p>Thalidomide </p> <p> <ol id="CD013767-list-0018"> <li> <p>somnolence and headache (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>) </p> </li> </ol> </p> <p>Decitabine </p> <p> <ol id="CD013767-list-0019"> <li> <p>respiratory tract infection (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> </ol> </p> <p>Resveratrol </p> <p> <ol id="CD013767-list-0020"> <li> <p>gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea and gastrointestinal bleeding, headache and malaise (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>) </p> </li> </ol> </p> <p>Radix Astragali </p> <p>None of the prespecified adverse drug effects (abnormalities to blood counts, liver enzymes levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>CNP </p> <p>None of the prespecified adverse drug effects (abnormalities to blood counts, liver enzymes levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (4 RCTs, 4 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CNP:</b> combined natural preparation; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision because data from only one small trial and the CIs included both appreciable benefit and appreciable harm.<br/><sup>b</sup>Downgraded two levels for imprecision because data were based on one small trial with very wide CIs.<br/><sup>c</sup>Downgraded one level for lack of blinding.<br/><sup>d</sup>Downgraded two levels for imprecision, data from only one small study with very small information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013767-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">One dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>One dose or dose regimen of an HbF inducer compared with another dose or dose regimen of the same HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in India<br/><b>Intervention:</b> 1 dose of an HbF inducer<br/><b>Comparison:</b> a different dose of the same HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 1 dose (lower) of HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another dose (higher) of HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/ year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported frequency of transfusion.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin with 10 mg/kg/day was <b>9.12 (SD 0.70)</b> <b>g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin with 20 mg/kg/day was<b>2.39 g/dL lower</b> (95% CI 2.80 lower to 1.98 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day.</p> <p>Not downgraded for lack of blinding because of outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF (%)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF for 10 mg/kg/day was <b>35.4% (SD 12.3%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF with 20 mg/kg/day was <b>10.20% lower</b> (95% CI 16.28% lower to 4.12% lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day.</p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(2 RCTs, 2 interventions, 6 different doses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day; 1 study compared 4 doses of HQK‐1001: 10 mg/kg/day; 20 mg/kg/day; 30 mg/kg/day; 40 mg/kg/day (for a summary of these findings at 2 months, see <a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>). </p> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia</b> </p> <p>(WBC &lt; 1 × 10<sup>3</sup>/μL, ANC &lt; 0.5 × 10<sup>3</sup>/μL) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000 with hydroxyurea 10 mg/kg/day</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> (42 to 1000) with hydroxyurea 20 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.93</b> (1.34 to 73.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutropenia would influence the decision to continue the intervention but not the decision to transfuse blood. </p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenia</b> </p> <p>(platelet count &lt; 50 × 10<sup>3</sup>/μL) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000 with hydroxyurea 10 mg/kg/day</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>345 per 1000</b> (105 to 1000) with hydroxyurea 20 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.68</b> (1.12 to 12.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia would influence the decision to continue the intervention but not the decision to transfuse blood. </p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ANC:</b> absolute neutrophil count; <b>CI:</b> confidence interval; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>WBC:</b> white blood cell count. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias because of unclear allocation concealment.<br/><sup>b</sup>Downgraded two levels for imprecision because data were based on one small trial with very small information size.<br/><sup>c</sup>Downgraded two levels for imprecision because data were based on one small trial with very wide CIs.<br/><sup>d</sup>Downgraded one level for indirectness because the follow‐up duration was short and insufficient to see changes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013767-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Two or more foetal haemoglobin inducers at any dose or duration compared with a usual management protocol, placebo or a single foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Two or more HbF inducers at any dose or duration compared with a usual management protocol, placebo or a single HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> outpatient clinics in Iran<br/><b>Intervention:</b> combined ≥ 2 HbF inducers </p> <p><b>Comparison:</b> single HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ≥ 2 HbF inducers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported frequency of transfusion.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin level</b> (g/dL) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level (g/dL) with a single HbF inducer ranged from <b>8.5 (SD 1.2) g/dL to 8.8 (SD 1.3) g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level with ≥ 2 HbF inducers was <b>0.74 g/dL lower</b><br/>(1.45 lower to 0.03 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 RCT, 3 intervention combinations) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The single HbF inducer here refers to either hydroxyurea or resveratrol alone.</p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF levels</b> (%) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported HbF levels.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Hydroxyurea vs resveratrol vs combined hydroxyurea plus resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>) </p> <p> <ol id="CD013767-list-0021"> <li> <p>gastrointestinal events including severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding </p> </li> <li> <p>headache</p> </li> <li> <p>malaise</p> </li> </ol> </p> <p>Hydroxyurea vs combined hydroxyurea plus l‐carnitine (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>) </p> <p> <ol id="CD013767-list-0022"> <li> <p>nausea and vomiting (6 participants)</p> </li> <li> <p>headache (1 participant)</p> </li> <li> <p>abdominal discomfort (1 participant)</p> </li> <li> <p>no changes to the biochemical parameters and blood counts</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(2 RCTs, 3 pair‐wise comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> reported adverse events, but data could not be separated from study arms that we had excluded from this review. </p> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomised controlled trial; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision because based on one small trial with very small information size.<br/><sup>b</sup>Downgraded two levels for risk of bias because unclear randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013767-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013767-sec-0009"></div> <section id="CD013767-sec-0010"> <h3 class="title" id="CD013767-sec-0010">Description of the condition</h3> <p>Thalassaemia is an inherited disease resulting in abnormal haemoglobin. This affects both the production and life span of red cells resulting in anaemia of varying degrees. It is found mainly in populations originating from malaria‐endemic areas (<a href="./references#CD013767-bbs2-0117" title="WeatherallDJ . The Thalassaemia Syndrome. 4th edition. Hoboken (NJ): Blackwell Science, 2001.">Weatherall 2001</a>), such as Africa (<a href="./references#CD013767-bbs2-0118" title="WeatherallDJ . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews2012;26(Suppl 1):S3-6. [DOI: 10.1016/S0268-960X(12)70003-6]">Weatherall 2012</a>), Asia (<a href="./references#CD013767-bbs2-0060" title="KohneE , KleihauerE . Hemoglobinopathies: a longitudinal study over four decades. Deutsches Arzteblatt International2010;107(5):65-71. [PMID: 20186311]">Kohne 2010</a>; <a href="./references#CD013767-bbs2-0118" title="WeatherallDJ . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews2012;26(Suppl 1):S3-6. [DOI: 10.1016/S0268-960X(12)70003-6]">Weatherall 2012</a>), and the Mediterranean (<a href="./references#CD013767-bbs2-0041" title="De SanctisV , KattamisC , CanatanC , SolimanAT , ElsedfyH , KarimiM , et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterranean Journal of Hematology and Infectious Diseases2017;9(1):e2017018.">De Sanctis 2017</a>). Globally, thalassaemia affects approximately 56,000 newborns annually (<a href="./references#CD013767-bbs2-0072" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480-7. [PMID: 18568278]">Modell 2008</a>), and a third of the population with thalassaemia is considered non‐transfusion‐dependent (NTD) (<a href="./references#CD013767-bbs2-0118" title="WeatherallDJ . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews2012;26(Suppl 1):S3-6. [DOI: 10.1016/S0268-960X(12)70003-6]">Weatherall 2012</a>). This population lies between those who require regular transfusion for survival (transfusion‐dependent thalassaemia (TDT)) and those who do not require transfusion beyond that of a person without the condition (carrier state or thalassaemia trait). The types of NTD thalassaemia include β‐thalassaemia intermedia, haemoglobin E combined with β‐thalassaemia (HbE/β‐thalassaemia) and haemoglobin H (HbH) disease. The β‐globin chain is affected in HbE/β‐thalassaemia and β‐thalassaemia intermedia, whereas α‐globin chain is affected in HbH disease (<a href="./references#CD013767-bbs2-0072" title="ModellB , DarlisonM . Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization2008;86(6):480-7. [PMID: 18568278]">Modell 2008</a>; <a href="./references#CD013767-bbs2-0118" title="WeatherallDJ . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews2012;26(Suppl 1):S3-6. [DOI: 10.1016/S0268-960X(12)70003-6]">Weatherall 2012</a>). The inheritance can be confirmed by Hb electrophoresis and DNA analysis for α‐ and β‐globin chain. </p> <p>In this review, β‐thalassaemia intermedia and HbE/β‐thalassaemia will be collectively referred to as non‐transfusion‐dependent β‐thalassaemia (NTDβT), the major contributors to NTD thalassaemia. They present with an extremely diverse clinical spectrum of chronic anaemia and face a risk of developing complications such as bone deformities, extramedullary haemopoiesis, pulmonary hypertension and hypercoagulable episodes (<a href="./references#CD013767-bbs2-0110" title="TaherAT , MusallamKM , KarimiM , El-BeshlawyA , BelhoulK , DaarS , et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood2010;115(10):1886-92. [PMID: 20032507]">Taher 2010</a>). These changes occur over a number of years. The diversity arises from multiple genetic differences that determine the lifespan of a haemoglobin molecule (<a href="./references#CD013767-bbs2-0033" title="CamaschellaC , CappelliniMD . Thalassemia intermedia. Haematologica1995;80(1):58-68. [PMID: 7758995]">Camaschella 1995</a>; <a href="./references#CD013767-bbs2-0061" title="KohneE . Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Deutsches Arzteblatt International2011;108(31-2):532-40. [PMID: 21886666]">Kohne 2011</a>), and the presence of persistent higher levels of foetal haemoglobin (HbF) (<a href="./references#CD013767-bbs2-0074" title="MusallamKM , SankaranVG , CappelliniMD , DucaL , NathanDG , TaherAT . Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia. Blood2012;119(2):364-7. [DOI: 10.1182/blood-2011-09-382408]">Musallam 2012</a>; <a href="./references#CD013767-bbs2-0117" title="WeatherallDJ . The Thalassaemia Syndrome. 4th edition. Hoboken (NJ): Blackwell Science, 2001.">Weatherall 2001</a>). The proportion of HbF could differ within one genetic variation (<a href="./references#CD013767-bbs2-0079" title="NuinoonM , MakarasaraW , MushirodaT , SetianingsihI , WahidiyatPA , SripichaiO , et al. A genome-wide association identified the common genetic variants influence disease severity in beta-thalassemia/hemoglobin E. Human Genetics2010;127(3):303-14. [PMID: 20183929]">Nuinoon 2010</a>; <a href="./references#CD013767-bbs2-0098" title="SankaranVG , OrkinSH . The switch from fetal to adult hemoglobin. Cold Spring Harbour Perspective Medicine2013;3(1):a011643. [DOI: 10.1101/cshperspect.a011643]">Sankaran 2013</a>), but since it has some functional properties, the persistence of HbF might be important in preventing red cell transfusion (<a href="./references#CD013767-bbs2-0036" title="CarrociniGC , ZamaroPJ , Bonini-DomingosCR . What influences Hb fetal production in adulthood?Revista Brasiliera de Hematologica e Hemoterapia2011;33(3):231-6. [DOI: 10.5581/1516-8484.20110059]">Carrocini 2011</a>; <a href="./references#CD013767-bbs2-0098" title="SankaranVG , OrkinSH . The switch from fetal to adult hemoglobin. Cold Spring Harbour Perspective Medicine2013;3(1):a011643. [DOI: 10.1101/cshperspect.a011643]">Sankaran 2013</a>). As a result, depending on the proportion and type of HbF, and its affinity for oxygen, a clinical spectrum is observed which ranges from mild asymptomatic anaemia to the occasional need for transfusion. </p> <p>Red blood cell (RBC) transfusion is the mainstay of treatment (<a href="./references#CD013767-bbs2-0026" title="AsadovC , AlimirzoevaZ , MammadovaT , AliyevaG , GafarovaS , MammadovJ . Beta-thalassemia intermedia: a comprehensive overview and novel approaches. International Journal of Hematology2018;108(1):5-21. [DOI: 10.1007/s12185-018-2411-9]">Asadov 2018</a>; <a href="./references#CD013767-bbs2-0029" title="Borgna-PignattiC . Modern treatment of thalassaemia intermedia. British Journal of Haematology2007;138(3):291-304. [PMID: 17565568]">Borgna‐Pignatti 2007</a>), and is determined by factors such as stunted growth and manifestation of extramedullary erythropoiesis in children; and during demanding conditions such as pregnancy and heart failure in adults (<a href="./references#CD013767-bbs2-0110" title="TaherAT , MusallamKM , KarimiM , El-BeshlawyA , BelhoulK , DaarS , et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood2010;115(10):1886-92. [PMID: 20032507]">Taher 2010</a>; <a href="./references#CD013767-bbs2-0112" title="TaherA , MusallamK , CappelliniMD . Chapter 2: Blood transfusion. In: TaherA , MusallamK , CappelliniMD , editors(s). Guidelines for Management of Non Transfusion Dependent Thalassemia (NTDT). 2nd edition. Nicosia (Cyprus): Thalassaemia International Federation, 2018:14-20. [ISBN: 978-9963-717-11-8]">TIF 2018a</a>). </p> <p>However, each transfusion will exacerbate the existing problem of high iron deposition from ongoing increased gut iron absorption secondary to the low hepcidin concentrations found in NTDβT (<a href="./references#CD013767-bbs2-0077" title="NemethE , GanzT . The role of hepcidin in iron metabolism. Acta Haematologica2009;122(2-3):78-86. [DOI: 10.1159/000243791]">Nemeth 2009</a>; <a href="./references#CD013767-bbs2-0081" title="OrigaR , GalanelloR , GanzT , GiaguN , MaccioniL , FaaG , et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica2007;92(5):583-8. [DOI: 10.3324/haematol.10842]">Origa 2007</a>; <a href="./references#CD013767-bbs2-0089" title="PippardMJ , CallenderST , WarnerGT , WeatherallDJ . Iron absorption and loading in beta-thalassaemia intermedia. Lancet1979;2(8147):819-21. [PMID: 90918]">Pippard 1979</a>) and haem breakdown (<a href="./references#CD013767-bbs2-0109" title="TaherAT , MusallamKM , CappelliniMD . Thalassaemia intermedia: an update. Mediterranean Journal of Hematology and Infectious Diseases2009;1(1):e2009004. [PMID: 21415986]">Taher 2009</a>); this causes iron overload and its complications, although it is less severe than in people with TDT (<a href="./references#CD013767-bbs2-0110" title="TaherAT , MusallamKM , KarimiM , El-BeshlawyA , BelhoulK , DaarS , et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood2010;115(10):1886-92. [PMID: 20032507]">Taher 2010</a>; <a href="./references#CD013767-bbs2-0117" title="WeatherallDJ . The Thalassaemia Syndrome. 4th edition. Hoboken (NJ): Blackwell Science, 2001.">Weatherall 2001</a>). Transfusion also increases risks of blood‐transmitted infections, RBC antibody formation, hypersensitivity reactions and cholecystitis. Chelating agents to remove excessive iron deposits are initiated at lower iron levels than that for TDT (<a href="./references#CD013767-bbs2-0109" title="TaherAT , MusallamKM , CappelliniMD . Thalassaemia intermedia: an update. Mediterranean Journal of Hematology and Infectious Diseases2009;1(1):e2009004. [PMID: 21415986]">Taher 2009</a>), but they too have their own disadvantages (<a href="./references#CD013767-bbs2-0030" title="BotzenhardtS , FelisiM , BonifaziD , Del VecchioGC , PuttiMC , KattamisA , et al. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. Haematologica2018;103(1):e1-4. [PMID: 29079595]">Botzenhardt 2018</a>; <a href="./references#CD013767-bbs2-0035" title="CappelliniMD , CohenA , PigaA , BejaouiM , PerrottaS , AgaogluL , et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood2006;107(9):3455-62.">Cappellini 2006</a>; <a href="./references#CD013767-bbs2-0047" title="FisherSA , BrunskillSJ , DoreeC , GoodingS , ChowdhuryO , RobertsDJ . Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004450. [DOI: 10.1002/14651858.CD004450.pub3] [PMID: 23963793]">Fisher 2013</a>). </p> </section> <section id="CD013767-sec-0011"> <h3 class="title" id="CD013767-sec-0011">Description of the intervention</h3> <p>HbF inducers are natural or synthetic agents which increase HbF levels without altering the globin gene sequence (<a href="./references#CD013767-bbs2-0028" title="BianchiN , ZuccatoC , LamprontiI , BorgattiM , GambariR . Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evidence-Based Complementary and Alternative Medicine: eCAM2009;6(2):141-51. [DOI: 10.1093/ecam/nem139]">Bianchi 2009</a>), such as preventing the replacement of HbF with adult haemoglobin and inhibiting the actions of transcription factor genes silencers (<a href="./references#CD013767-bbs2-0114" title="UdaM , GalanelloR , SannaS , LettreG , SankaranVG , ChenW , et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proceedings of the National Academy of Sciences of the United States of America2008;105(5):1620-5. [DOI: 10.1073/pnas.0711566105]">Uda 2008</a>), or enzymes that regulate γ‐globin expression (<a href="./references#CD013767-bbs2-0046" title="FardAD , HosseiniSA , ShahjahaniM , SalariF , JasebK . Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. International Journal of Hematology, Oncology and Stem Cell Research2013;7(3):47-54.">Fard 2013</a>; <a href="./references#CD013767-bbs2-0098" title="SankaranVG , OrkinSH . The switch from fetal to adult hemoglobin. Cold Spring Harbour Perspective Medicine2013;3(1):a011643. [DOI: 10.1101/cshperspect.a011643]">Sankaran 2013</a>; <a href="./references#CD013767-bbs2-0103" title="ShearstoneJR , GolonzhkaO , ChonkarA , TamangD , vanDuzerJH , JonesSS , et al. Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2. PLOS One2016;11(4):e0153767. [DOI: 10.1371/ journal.pone.0153767]">Shearstone 2016</a>; <a href="./references#CD013767-bbs2-0120" title="WittO , MönkemeyerS , RönndahlG , ErdlenbruchB , ReinhardtD , KanbachK , et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood2003;101(5):2001-7. [DOI: 10.1182/blood-2002-08-2617]">Witt 2003</a>). </p> <p>In a number of studies in people with β‐thalassaemia, HbF inducers have been found to increase haemoglobin and reduce blood transfusion (<a href="./references#CD013767-bbs2-0031" title="BradaiM , AbadMT , PissardS , LamraouiF , SkopinskiL , deMontalembertM . Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood2003;102(4):1529-30.">Bradai 2003</a>; <a href="./references#CD013767-bbs2-0105" title="SingerST , KuypersFA , OlivieriNF , WeatherallDJ , MignaccaR , CoatesTD , et al. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: considerations for treatment. Annals of the New York Academy of Sciences2005;1054:250-6.">Singer 2005a</a>). Therapies to raise hepcidin levels and erythroid cell maturating agents are alternative approaches to the use of HbF inducers to reduce the need for transfusion in people with thalassaemia, but such interventions are still under investigation (<a href="./references#CD013767-bbs2-0037" title="CasuC , NemethE , RivellaS . Hepcidin agonists as therapeutic tools. Blood2018;131(16):1790-4. [DOI: 10.1182/blood-2017-11-737411]">Casu 2018</a>; <a href="./references#CD013767-bbs2-0111" title="TaherAT , CappelliniMD . Luspatercept for β-thalassemia: beyond red blood cell transfusions. Expert Opinion on Biological Therapy2021;21(11):1363-71. [DOI: 10.1080/14712598.2021.1968825]">Taher 2021</a>). One such therapy is luspatercept, an erythrocyte‐maturing agent (<a href="./references#CD013767-bbs2-0037" title="CasuC , NemethE , RivellaS . Hepcidin agonists as therapeutic tools. Blood2018;131(16):1790-4. [DOI: 10.1182/blood-2017-11-737411]">Casu 2018</a>). </p> <p>Hydroxyurea, a ribonucleotide reductase inhibitor, is the most widely studied inducer for people with NTDβT, sickle cell disease (SCD) (<a href="./references#CD013767-bbs2-0091" title="Rankine-MullingsAE , NevittSJ . Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD002202. [DOI: 10.1002/14651858.CD002202.pub3]">Rankine‐Mullings 2022</a>) and TDT (<a href="./references#CD013767-bbs2-0025" title="AnsariSH , LassiZS , KhowajaSM , AdilS , ShamsiTS . Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD012064. [DOI: 10.1002/14651858.CD012064.pub2]">Ansari 2019</a>), and is the only one that is currently in use for NTDβT. It has been included in a guideline published by the Thalassaemia International Federation (<a href="./references#CD013767-bbs2-0113" title="TaherA , MusallamK , CappelliniMD . Chapter 4: Splenectomy. In: TaherA , MusallamK , CappelliniMD , editors(s). Guidelines for Management of Non Transfusion Dependent Thalassemia (NTDT). 2nd edition. Nicosia, Cyprus: Thalassaemia International Federation, 2018:30-8. [ISBN: 978-9963-717-11-8]">TIF 2018b</a>). Other promising inducers include histone deacetylase (HDAC) inhibitors (<a href="./references#CD013767-bbs2-0071" title="MigliaccioAR , RotiliD , NebbiosoA , AtwehG , MaiA . Histone deacetylase inhibitors and hemoglobin F induction in β-thalassemia. International Journal of Biochemistry &amp; Cell Biology2008;11(40):2341-7. [DOI: 10.1016/j.biocel.2008.04.024]">Migliaccio 2008</a>), such as butyrates (<a href="./references#CD013767-bbs2-0088" title="PerrineSP , WarginWA , BoosalisMS , WallisWJ , CaseS , KeeferJR , et al. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. Journal of Clinical Pharmacology2011;51(8):1186-94. [PMID: 21422239]">Perrine 2011</a>; <a href="./references#CD013767-bbs2-0092" title="ReidME , El BeshlawyA , InatiA , KutlarA , AbboudMR , Haynes J Jr, et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology2014;89(7):709-13.">Reid 2014</a>), short fatty acids (<a href="./references#CD013767-bbs2-0082" title="PaceBS , WhiteGL , DoverGJ . Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood2002;100(13):4640-8. [DOI: 10.1182/blood-2002-02-0353]">Pace 2002</a>), decitabine (<a href="./references#CD013767-bbs2-0057" title="KalantriSA , RayR , ChattopadhyayA , BhattacharjeeS , BiswasA , BhattacharyyaM . Efficacy of decitabine as haemoglobin F inducer in HbE/β-thalassemia. Annals of Hematology2018;97(9):1689-94. [DOI: 10.1007/s00277-018-3357-y]">Kalantri 2018</a>; <a href="./references#CD013767-bbs2-0080" title="OlivieriNF , SaunthararajahY , ThayalasuthanV , KwiatkowskiJ , WareRE , KuypersFA , et al. A pilot study of subcutaneous decitabine in β-thalassemia. Blood2011;118(10):2708-11.">Olivieri 2011</a>), and valproate acid (<a href="./references#CD013767-bbs2-0101" title="SelbyR , Nisbet-BrownE , BasranRK , ChangL , OlivieriNF . Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood1997;90(2):891-2.">Selby 1997</a>); immunomodulators such as thalidomide (<a href="./references#CD013767-bbs2-0022" title="AerbajinaiW , ZhuJ , GaoZ , ChinK , RodgersGP . Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood2007;110(8):2864-71. [DOI: 10.1182/blood-2007-01-065201] [PMID:17620452; PMCID: PMC2018668]">Aerbajinai 2007</a>); and natural agents (<a href="./references#CD013767-bbs2-0096" title="RodrigueCM , ArousN , BachirD , Smith-RavinJ , RomeoPH , GalacterosF , et al. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. British Journal of Haematology2001;113(2):500-7. [DOI: 10.1046/j.1365-2141.2001.02746.x]">Rodrigue 2001</a>), such as resveratrol (<a href="./references#CD013767-bbs2-0028" title="BianchiN , ZuccatoC , LamprontiI , BorgattiM , GambariR . Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evidence-Based Complementary and Alternative Medicine: eCAM2009;6(2):141-51. [DOI: 10.1093/ecam/nem139]">Bianchi 2009</a>), l‐carnitine (<a href="./references#CD013767-bbs2-0087" title="PerrineSP , MillerBA , FallerDV , CohenRA , VichinskyEP , HurstD , et al. Sodium butyrate enhances fetal globin gene expression inerythroid progenitors of patients with Hb SS and beta thalassemia. Blood1989;74(1):454-9. [PMID: 2473801]">Perrine 1989</a>), Yisui Shengxue granules (YSSXG) (<a href="./references#CD013767-bbs2-0039" title="ChengYL , ZhangXH , SunYW , WangWJ , FangSP , WuZK . Clinical effect and mechanism of Yisui Shengxue granules in thalassemia patients with mild, moderate, or severe anemia. Evidence-Based Complementary and Alternative Medicine2016;2016:1713897. [DOI: 10.1155/2016/1713897] [PMID: 26949404]">Cheng 2016</a>), bergamot (<a href="./references#CD013767-bbs2-0051" title="GuerriniA , LamprontiI , BianchiN , ZuccatoC , BreveglieriG , SalvatoriF , et al. Bergamot (Citrus bergamia Risso) fruit extracts as gamma-globin gene expression inducers: phytochemical and functional perspectives. Journal of Agricultural and Food Chemistry2009;57(10):4103-11. [PMID: 19371028]">Guerrini 2009</a>), and Fructus <i>Trichosanthis</i> (<a href="./references#CD013767-bbs2-0065" title="LiH , KoCH , TsangSY , LeungPC , FungMC , FungKP . The ethanol extract of fructus trichosanthis promotes fetal hemoglobin production via p38 MAPK activation and ERK inactivation in K562 cells. Evidence-Based Complementary and Alternative Medicine: eCAM2011;2011:657056. [DOI: 10.1093/ecam/neq022] [PMID: 21876711]">Li 2011</a>), but their usages are mainly in the experimental phase. </p> <p>All are administered orally, except decitabine which is given subcutaneously. Information is sparse about the duration needed for each inducer to exert its peak response and maintain its effectiveness beyond the last therapeutic dose (<a href="./references#CD013767-bbs2-0075" title="MusallamKM , TaherAT , CappelliniMD , SankaranVG . Clinical experience with fetal hemoglobin induction therapy in patients with b-thalassemia. Blood2013;121(12):2199-212.">Musallam 2013a</a>; <a href="./references#CD013767-bbs2-0107" title="SteinbergMH , McCarthyWF , CastroO , BallasSK , ArmstrongFD , SmithW , et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology2010;85(6):403-8. [DOI: 10.1002/ajh.21699]">Steinberg 2010</a>). Hydroxyurea is effective within six months of treatment (<a href="./references#CD013767-bbs2-0059" title="KinneyTR , HelmsRW , O'BranskiEE , Ohene-FrempongK , WangW , DaeschnerC , et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood1999;94(5):1550-4. [PMID: 10477679]">Kinney 1999</a>; <a href="./references#CD013767-bbs2-0108" title="StrouseJJ , HeeneyMM . Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric Blood Cancer2012;59(2):365-71. [PMID: 22517797]">Strouse 2012</a>; <a href="./references#CD013767-bbs2-0125" title="ZimmermanSA , SchultzWH , DavisJS , PickensCV , MortierNA , HowardTA , et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood2004;103(6):2039-45. [PMID: 14630791]">Zimmerman 2004</a>), and reaches its peak levels within four hours of ingestion (<a href="./references#CD013767-bbs2-0038" title="CharacheS , DoverGJ , MooreRD , EckertS , BallasSK , KoshyM , et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood1992;79(10):2555-65. [PMID: 1375104]">Charache 1992</a>), but the duration of effect is uncertain. Two observational studies suggested hydroxyurea loses its efficacy after 12 months (<a href="./references#CD013767-bbs2-0069" title="MancusoA , MaggioA , RendaD , Di MarzoR , RiganoP . Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology2006;133(1):105-6. [PMID: 16512837]">Mancuso 2006</a>; <a href="./references#CD013767-bbs2-0095" title="RiganoP , PecoraroA , CalzolariR , TroiaA , AcutoS , RendaD , et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology2010;151(5):509-15. [PMID: 20955403]">Rigano 2010</a>). However, one study has suggested improved outcomes up to 24 months (<a href="./references#CD013767-bbs2-0056" title="ItaliaKY , JijinaFJ , MerchantR , PanjwaniS , NadkarniAH , SawantPM , et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clinica Chimica Acta: International Journal of Clinical Chemistry2009;407(1-2):10-5. [DOI: 10.1016/j.cca.2009.06.019]">Italia 2009</a>). There are no data beyond 24 months. Decitabine may be effective within two weeks (<a href="./references#CD013767-bbs2-0080" title="OlivieriNF , SaunthararajahY , ThayalasuthanV , KwiatkowskiJ , WareRE , KuypersFA , et al. A pilot study of subcutaneous decitabine in β-thalassemia. Blood2011;118(10):2708-11.">Olivieri 2011</a>), and its efficacy is sustained for eight weeks (<a href="./references#CD013767-bbs2-0057" title="KalantriSA , RayR , ChattopadhyayA , BhattacharjeeS , BiswasA , BhattacharyyaM . Efficacy of decitabine as haemoglobin F inducer in HbE/β-thalassemia. Annals of Hematology2018;97(9):1689-94. [DOI: 10.1007/s00277-018-3357-y]">Kalantri 2018</a>). It has been reported that YSSXG may sustain its efficacy for four weeks. Details about other inducers remain uncertain and these are still at an experimental stage. Most inducers do not have follow‐up data beyond six months. Their effectiveness could also be influenced by genetic variations (<a href="./references#CD013767-bbs2-0075" title="MusallamKM , TaherAT , CappelliniMD , SankaranVG . Clinical experience with fetal hemoglobin induction therapy in patients with b-thalassemia. Blood2013;121(12):2199-212.">Musallam 2013a</a>; <a href="./references#CD013767-bbs2-0090" title="PourfarzadF , vonLindernM , AzarkeivanA , HouJ , KiaSK , EsteghamatF , et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica2013;98(5):696-704. [DOI: 10.3324/haematol.2012.074492]">Pourfarzad 2013</a>), and pretreatment HbF levels (<a href="./references#CD013767-bbs2-0090" title="PourfarzadF , vonLindernM , AzarkeivanA , HouJ , KiaSK , EsteghamatF , et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica2013;98(5):696-704. [DOI: 10.3324/haematol.2012.074492]">Pourfarzad 2013</a>). </p> <p>Each inducer has its own reported adverse effects, which could be dose‐dependent, transient or reversible after discontinuing treatment (<a href="./references#CD013767-bbs2-0108" title="StrouseJJ , HeeneyMM . Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric Blood Cancer2012;59(2):365-71. [PMID: 22517797]">Strouse 2012</a>; <a href="./references#CD013767-bbs2-0125" title="ZimmermanSA , SchultzWH , DavisJS , PickensCV , MortierNA , HowardTA , et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood2004;103(6):2039-45. [PMID: 14630791]">Zimmerman 2004</a>); these include neutropenia, oligospermia, skin rashes with hydroxyurea (<a href="./references#CD013767-bbs2-0125" title="ZimmermanSA , SchultzWH , DavisJS , PickensCV , MortierNA , HowardTA , et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood2004;103(6):2039-45. [PMID: 14630791]">Zimmerman 2004</a>); gastrointestinal disturbances, headache, elevated liver enzymes with HQK‐1001 (<a href="./references#CD013767-bbs2-0084" title="PatthamalaiP , FuchareonS , ChaneiamN , GhalieRG , ChuiDH , BoosalisMS , et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood2014;123(12):1956-7.">Patthamalai 2014</a>); carcinogenic effects, the thrombotic risk with decitabine (<a href="./references#CD013767-bbs2-0080" title="OlivieriNF , SaunthararajahY , ThayalasuthanV , KwiatkowskiJ , WareRE , KuypersFA , et al. A pilot study of subcutaneous decitabine in β-thalassemia. Blood2011;118(10):2708-11.">Olivieri 2011</a>); rash (<a href="./references#CD013767-bbs2-0093" title="RenQ , ZhouYL , WangL , ChenYS , MaYN , LiPP , et al. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of Hematology2018;97(10):1933-9. [DOI: 10.1007/s00277-018-3395-5] [PMID: 29931453.]">Ren 2018</a>), and teratogenic effects with thalidomide. </p> <p>Inducers have been prescribed to children with NTDβT but the optimal age for initiating therapy and the appropriate dose is unknown (<a href="./references#CD013767-bbs2-0032" title="BradaiM , PissardS , AbadMT , DechartresA , RibeilJA , LandaisP , et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion2007;47(10):1830-6. [PMID: 17880608]">Bradai 2007</a>; <a href="./references#CD013767-bbs2-0116" title="WangWJ , WuZK , ZhangXH , WangRX , LiuYM , FangSP , et al. Observations on after-effect duration of kidney-nourishing and marrow-replenishing therapy on 58 cases of Mediterranean anemia. Journal of Traditional Chinese Medicine (Chung i Tsa Chih Ying Wen Pan)2009;29(4):258-62. [PMID: 20112483]">Wang 2009</a>). Some inducers may have additional antioxidant properties possibly reducing erythrocyte destruction (<a href="./references#CD013767-bbs2-0078" title="NgNY , KoCH . Natural remedies for the treatment of beta-thalassemia and sickle cell anemia-current status and perspectives in fetal hemoglobin reactivation. International Scholarly Research Notices2014;2014:123257. [PMID: 27350962]">Ng 2014</a>). Combinations of inducers may have synergistic effects (<a href="./references#CD013767-bbs2-0106" title="SingerST , KuypersFA , OlivieriNF , WeatherallDJ , MignaccaR , CoatesTD , et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. British Journal of Haematology2005;131(3):378-88. [PMID: 16225658]">Singer 2005b</a>). </p> </section> <section id="CD013767-sec-0012"> <h3 class="title" id="CD013767-sec-0012">How the intervention might work</h3> <p>HbF is highest during foetal life and after birth there is a natural decline. In people with β‐thalassaemia, defective haemoglobins are produced once the HbF level has declined. High levels of HbF have been found to reduce the complications of chronic anaemia (<a href="./references#CD013767-bbs2-0049" title="GamberiniMR , FortiniM , De SanctisV . Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatric Endocrinology Reviews2004;2(Suppl 2):319-22. [PMID: 16462721]">Gamberini 2004</a>; <a href="./references#CD013767-bbs2-0070" title="MeoA , CassinerioE , CastelliR , BignaminiD , PeregoL , CappelliniMD . Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. International Journal of Laboratory Hematology2008;30(5):425-31. [PMID: 19046318]">Meo 2008</a>), and the need for transfusion (<a href="./references#CD013767-bbs2-0032" title="BradaiM , PissardS , AbadMT , DechartresA , RibeilJA , LandaisP , et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion2007;47(10):1830-6. [PMID: 17880608]">Bradai 2007</a>; <a href="./references#CD013767-bbs2-0062" title="KosaryanM , KaramiH , ZafariM , YaghobiN . Report on patients with non transfusion-dependent beta-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin2014;38(2):115-8. [PMID: 24471558]">Kosaryan 2014</a>). The mechanisms that enhance the activity and expression of RBC gamma‐globin (γ‐globin), a major component of HbF (α<sub>2</sub>γ<sub>2</sub>) could raise HbF levels. This rise in turn could help to stabilise the imbalance of the α/β chain, thus improving ineffective erythropoiesis, reducing RBC haemolysis and causing a lesser degree of anaemia; and ultimately, resulting in a reduction in the need of blood transfusion. This is why higher levels HbF are found in people with β‐thalassaemia and why HbF inducers might be an effective treatment to reduce blood transfusions. </p> <p>The effect of HbF inducers on haemoglobin varies and may be affected by different doses or types of inducers. There is little information if any about the onset or duration of effect (<a href="./references#CD013767-bbs2-0055" title="HoppeC , VichinskyE , LewisB , FooteD , StylesL . Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. American Journal of Hematology1999;62(4):221-7.">Hoppe 1999</a>; <a href="./references#CD013767-bbs2-0105" title="SingerST , KuypersFA , OlivieriNF , WeatherallDJ , MignaccaR , CoatesTD , et al. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: considerations for treatment. Annals of the New York Academy of Sciences2005;1054:250-6.">Singer 2005a</a>). </p> </section> <section id="CD013767-sec-0013"> <h3 class="title" id="CD013767-sec-0013">Why it is important to do this review</h3> <p>Considering the problems faced with blood transfusion, the use of therapies aimed at increasing HbF has become of interest and if found to be safe and effective could impact the quality of life (QoL) by reducing blood transfusion. HbF inducers, mainly hydroxyurea, have already been recommended in guidelines (<a href="./references#CD013767-bbs2-0113" title="TaherA , MusallamK , CappelliniMD . Chapter 4: Splenectomy. In: TaherA , MusallamK , CappelliniMD , editors(s). Guidelines for Management of Non Transfusion Dependent Thalassemia (NTDT). 2nd edition. Nicosia, Cyprus: Thalassaemia International Federation, 2018:30-8. [ISBN: 978-9963-717-11-8]">TIF 2018b</a>). It remains uncertain what their impact might have on healthcare resources, such as cost of treatment, human resources and blood bank reserves. It is possible that this intervention could completely change how this unique population is managed. A systematic assessment of the benefits and harms is essential to provide appropriate recommendations for people with NTDβT. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013767-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013767-sec-0014"></div> <p>To compare the effectiveness and safety of the following for reducing blood transfusion for people with NTDβT: </p> <p> <ol id="CD013767-list-0023"> <li> <p>HbF inducers versus usual care or placebo;</p> </li> <li> <p>a single HbF inducer with another HbF inducer, and single dose with another dose; and </p> </li> <li> <p>combination HbF inducers versus usual care or placebo, or a single HbF inducer.</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013767-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013767-sec-0015"></div> <section id="CD013767-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013767-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD013767-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of any age who have been defined as having NTDβT, either β‐thalassaemia intermedia or Hb E/β‐thalassaemia. </p> <p>Since there is a wide range of transfusion‐dependency ranging from occasional to regular transfusion during certain circumstances, NTDβT is difficult to define. For this review, we considered NTD to be present when an individual had one of the above‐mentioned conditions and transfusion was based on circumstances such as poor growth, excessive extramedullary haemopoiesis, severe infection and pregnancy. </p> <p>We described the ages of the included participants.</p> </section> <section id="CD013767-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD013767-list-0024"> <li> <p>A single HbF inducer at any dose or duration compared with usual care<sup>a</sup> or placebo. </p> </li> <li> <p>A single HbF inducer at any dose or duration compared with another HbF inducer.</p> </li> <li> <p>A single dose or dose regimen of an HbF inducer compared with another dose or dose regimen of the same HbF inducer. </p> </li> <li> <p>Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer. </p> </li> </ol> </p> <p><sup>a</sup>We defined usual care in this review as a standard management protocol that might include regular surveillance to identify chronic anaemia or when blood transfusion might be needed. </p> <p>We may need to revise the types of interventions included in the future updates of this Cochrane Review as more information about the precise mechanism of action of these substances becomes better known. Specifically, we did not include interventions that would normally be classified as gene therapy. We also excluded treatment modalities such as splenectomy, stem cell therapy, erythropoiesis enhancers and the use of other blood products. </p> <p>We excluded studies where the intervention period was too short to have a measurable effect, which may have varied between different HbF inducers depending on their mode of action (<a href="#CD013767-sec-0011">Description of the intervention</a>). </p> </section> <section id="CD013767-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We planned to assess the following outcome measures.</p> <section id="CD013767-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013767-list-0025"> <li> <p>Blood transfusion</p> <ol id="CD013767-list-0026"> <li> <p>frequency of transfusion measured by transfused volume per year (if there are insufficient data to calculate this, we planned to report this as units transfused per kg per year or other similar measures) </p> </li> <li> <p>transfusion‐free interval (in months)</p> </li> </ol> </li> <li> <p>Haemoglobin level (in grams per decilitre or equivalent at intervals after commencing the intervention, e.g. every three to six months) </p> </li> </ol> </p> </section> <section id="CD013767-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013767-list-0027"> <li> <p>HbF level (%) at intervals after commencing the intervention (e.g. every three to six months) </p> </li> <li> <p>Long‐term sequelae of NTDβT (at the longest time point reported by study authors)</p> <ol id="CD013767-list-0028"> <li> <p>growth</p> </li> <li> <p>puberty</p> </li> <li> <p>maxillary hyperplasia</p> </li> <li> <p>severity of extramedullary haematopoiesis (liver and spleen size)</p> </li> <li> <p>pulmonary hypertension</p> </li> </ol> </li> <li> <p>Quality of life (QoL) (physical, psychological, social relationship and environmental (e.g. the World Health Organization Quality of Life (WHOQOL) (<a href="./references#CD013767-bbs2-0119" title="World Health Organization. The World Health Organization Quality of Life (WHOQOL). www.who.int/mental_health/publications/whoqol/en/ (accessed 8 October 2020).">WHO 2012</a>)) (at the longest time point) </p> </li> <li> <p>Adverse outcomes (reported at any time during the study)</p> <ol id="CD013767-list-0029"> <li> <p>iron overload (such as by serum ferritin measurement)</p> </li> <li> <p>need for iron chelation (at any time during the study)</p> </li> <li> <p>adverse drug effects</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD013767-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished studies without restrictions on language, year or publication status. </p> <section id="CD013767-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Information Specialist conducted a systematic search of the Group's Haemoglobinopathies Trials Register for relevant studies using the following terms: ((thalassaemia:kw) OR ((haemoglobinopathies AND general):kw)) AND ((foetal haemoglobin:kw) OR (hydroxurea OR resveratrol* OR YiSui* OR bergamot OR fructus* OR Valproic acid:kw) OR (((fetal OR foetal) AND (haemoglobin OR hemoglobin)) OR hbf:ti,ab,em,mh)). </p> <p>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Public Health Agency Annual Scientific Meeting (formerly known as the Caribbean Health Research Council Meetings) and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's website (<a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">cfgd.cochrane.org/our-specialised-trials-registers</a>). </p> <p>Date of most recent search: 16 September 2022.</p> <p>We also searched the following databases and study registries:</p> <p> <ol id="CD013767-list-0030"> <li> <p>CENTRAL in the Cochrane Library (searched 21 August 2022);</p> </li> <li> <p>PubMed (<a href="https://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">www.ncbi.nlm.nih.gov/pubmed/</a>; 1946 to 21 August 2022); </p> </li> <li> <p>Embase Ovid (1974 to 21 August 2022);</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 21 August 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; searched 21 August 2022). </p> </li> </ol> </p> <p>For details of our search strategies, see <a href="./appendices#CD013767-sec-0138">Appendix 1</a>. </p> </section> <section id="CD013767-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. We contacted the authors of included trials in an attempt to identify further trials they may be involved in. </p> <p>We were made aware of four Chinese language databases (China Network Knowledge Infrastructure (CNKI) (<a href="https://www.cnki.net/" target="_blank">www.cnki.net/</a>); Chinese Scientific Journals Database (VIP) (<a href="https://www.cqvip.com/" target="_blank">www.cqvip.com/</a>); Wan Fang data (<a href="https://www.wanfangdata.com.cn/index.html" target="_blank">www.wanfangdata.com.cn/index.html</a>); and SinoMed (<a href="https://www.sinomed.ac.cn/" target="_blank">www.sinomed.ac.cn/</a>)). We could access three of the databases (CNKI, VIP, Wan Fang), but not SinoMed. We searched these databases using simple keywords 地中海贫血症 (thalassaemia), HbF 诱导剂 (HbF inducer), 随机对照试验 (RCT). </p> <p>Date of most recent search: 21 August 2022.</p> </section> </section> <section id="CD013767-sec-0026"> <h3 class="title" id="CD013767-sec-0026">Data collection and analysis</h3> <section id="CD013767-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (WCF, CKL, DL) independently screened the results (titles and abstracts) of the literature search for potentially relevant studies. We retrieved full reports of the potentially relevant studies and independently determined if they meet the review's predefined inclusion criteria using a pretested eligibility form (<a href="./references#CD013767-bbs2-0064" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022</a>). We resolved discrepancies through discussion, and on several occasions consulted a fourth review author (JJH). We also consulted an editor within the Cochrane Cystic Fibrosis and Genetic Disorders Group where necessary. We contacted study authors and co‐authors for further information when a study eligibility was unclear. We listed all excluded studies and documented the reason for excluding them in the <a href="./references#CD013767-sec-0150" title="">Characteristics of excluded studies</a> table (<a href="./references#CD013767-bbs2-0066" title="LiT , HigginsJP , DeeksJJ . Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Li 2022</a>; <a href="./references#CD013767-bbs2-0094" title="Review Manager (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD013767-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from the included studies onto a specially designed data collection form. Three review authors (WCF, CKL and DL) independently collected study details and outcome data. We then entered the information into the agreed form, compared results and resolved any disagreements by discussion, and if required by consultation with a fourth review author (JJH). We extracted the following details: </p> <p> <ol id="CD013767-list-0031"> <li> <p>general information (title, authors, source, country, year of publication, setting);</p> </li> <li> <p>study characteristics (design, risk of bias);</p> </li> <li> <p>participant characteristics (inclusion and exclusion criteria, type of NTDβT, severity of anaemia, indication for HbF inducer, ongoing usual care including the indication for blood transfusion, sample size, losses to follow‐up, baseline characteristics such as age, ethnic group, pre‐existing comorbidities, duration of transfusion, prior splenectomy and iron chelation); </p> </li> <li> <p>intervention (data regarding the usage of HbF inducers, e.g. amount, frequency of delivery, timing from diagnosis, length of treatment, participant responsiveness); </p> </li> <li> <p>comparison (data regarding usual care with or without a placebo; in studies using placebo, we collected data on amount and frequency of delivery); </p> </li> <li> <p>other outcomes as specified under <a href="#CD013767-sec-0020">Types of outcome measures</a>; and </p> </li> <li> <p>additional data (adverse events, QoL measurements and outcomes not described under <a href="#CD013767-sec-0020">Types of outcome measures</a>); for each study, we extracted data on adverse drug effects prespecified in the study protocol or methods and adverse drug effects reported in the results or discussion. </p> </li> </ol> </p> <p>Where necessary we contacted the original investigators in an effort to obtain any data that needed further clarification or was not reported. </p> <p>We planned to group outcome data into specific time periods depending on what was reported. We also grouped studies using different doses of the same HbF inducer or different combinations of HbF inducers accordingly. </p> <p>For multiple‐arm studies, we only included the relevant arms that involved an HbF inducer as part of the intervention in one or more groups (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). For the three‐arm study comparing two different HbF inducers to placebo, we included both arms in a single analysis by dividing the placebo group between the two intervention groups (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). For the three‐arm study comparing two different HbF inducers to a combined HbF inducer, we included both arms in a single analysis by dividing the combined HbF inducer group between the HbF intervention groups (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </section> <section id="CD013767-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (WCF, CKL, DL) independently assessed the risk of bias of each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013767-bbs2-0053" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We resolved any disagreements by discussion with a fourth review author (JJH). Where there was inadequate information to make a judgement, we attempted to correspond with the study authors. </p> <p>For each study included, we assessed the following criteria.</p> <p> <div class="table" id="CD013767-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assessment method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We described the methods used to generate the allocation sequence in terms of sufficient details and appropriateness. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0032"> <li> <p>Low risk of bias (any truly random process, e.g. random number table; computer random number generator) </p> </li> <li> <p>High risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number) </p> </li> <li> <p>Unclear risk of bias</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We described the methods used to conceal allocation to interventions prior to assignment to judge whether the intervention allocation could have been foreseen in advance of, during recruitment or changed after assignment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0033"> <li> <p>Low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes) </p> </li> <li> <p>High risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth) </p> </li> <li> <p>Unclear risk of bias</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding to treatment</p> <p>(of clinician (person delivering the treatment), participant and outcome assessors)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We described the methods used, if any, to blind participants and personnel from knowledge of which a participant received. We made a judgement on whether the blinding was adequate. We judged each outcome to be either subjective or objective based on whether we considered lack of blinding could affect the measurement of the outcome. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect the results. We assessed blinding separately for objective and subjective outcomes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0034"> <li> <p>Low, high or unclear risk of bias for participants</p> </li> <li> <p>Low, high or unclear risk of bias for personnel</p> </li> <li> <p>Low, high or unclear risk of bias for outcome assessors</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completeness of the outcome data</p> <p>(possible attrition bias through withdrawals, loss to follow‐up and protocol violations)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We described whether there were significant missing outcome data based on the number of participants recruited or randomised and the number analysed for each outcome at the end of the study period. If the percentage loss to follow‐up exceeded 10%, we made a decision to use an appropriate sensitivity analysis. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0035"> <li> <p>Low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups) </p> </li> <li> <p>High risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation) </p> </li> <li> <p>Unclear risk of bias</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective reporting bias (whether all prespecified outcomes and all expected outcomes of interest to the review were reported) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We attempted to describe how we investigated the possibility of selective outcome reporting bias and what we found including non‐significant results that were not reported adequately or missed important outcome variables. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0036"> <li> <p>Low risk of bias (where it was clear that all the study's prespecified outcomes and all expected outcomes of interest to the review had been reported) </p> </li> <li> <p>High risk of bias (where not all the study's prespecified outcomes had been reported; ≥ 1 reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported) </p> </li> <li> <p>Unclear risk of bias</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other sources of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We described any important concerns we had about other possible sources of bias such as baseline discrepancies and the possibility of skewed data. For sequential dose‐escalation or cross‐over studies, we assessed the risk of bias related to the washout period by taking into consideration the intervention's half‐life, any possibility of carry‐over effects and the potential life span of thalassaemia erythrocytes. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0037"> <li> <p>Low risk of other bias</p> </li> <li> <p>High risk of other bias</p> </li> <li> <p>Unclear whether there is risk of other bias</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> </p> <p>We made a judgement on the overall risk of bias assessment (based on the items above). We made explicit judgements whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013767-bbs2-0053" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). With reference to the domains we assessed, we judged the likely magnitude and direction of the bias and whether we considered it as likely to impact the findings. We explored the impact of the level of bias through undertaking sensitivity analysis. We used the overall risk of bias as part of grading the certainty of evidence for the summary of findings tables. </p> </section> <section id="CD013767-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We would have reported frequency of transfusion in millilitres per year, as a mean difference (MD) or if reported as a rate, as a rate ratio. We would have analysed a further primary outcome 'transfusion‐free interval' as time‐to‐event data and calculated the hazard ratio (HR). </p> <p>For dichotomous data, we presented the results as a summary risk ratio (RR).</p> <p>For continuous outcomes (all other outcomes listed above), where outcomes were measured in the same way between studies, we reported the mean relative change from baseline or the mean postintervention value. If we had encountered outcomes reported on different scales, such as QoL scales, we would have made a judgement whether they were reporting the same measure and, therefore, could be reasonably combined. Such data analyses would have been done by using standardised mean difference (SMD). </p> <p>We reported 95% confidence intervals (CI) for all measures of treatment effect.</p> </section> <section id="CD013767-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We treated the participant as the unit of analysis (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). We included dose‐escalation studies and would have included cross‐over studies. </p> <p>For dose‐escalation or cross‐over studies, we examined the washout period and assessed the adequacy and whether there would be any carryover effect. </p> <p>If we had encountered cluster‐RCTs, we had planned to follow the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013767-bbs2-0054" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). We would have used an estimate of the intracluster correlation coefficient (ICC) derived from the study (if possible), or from another source. </p> <p>For multiple‐arm studies (studies using one or more treatment groups), we selected only those arms that were relevant to the review. Where relevant we would have combined groups to create a single pair‐wise comparison using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013767-bbs2-0053" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). When a multiple‐arm study contributed more than one comparison to a particular meta‐analysis, we divided the control group between the two intervention groups. </p> </section> <section id="CD013767-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For missing or unclear data, we attempted to contact the authors. We contacted 12 investigators and two institutions for additional information on all the included studies (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), one excluded study (<a href="./references#CD013767-bbs2-0014" title="LiY , HeH , YangL , LiX , LiD , LuoS . Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia. International Journal of Hematology2016;104(5):559-65. [PMID: 27456464]NCT02772016. Therapeutic effect of colla corii asini on improving anemia and hemoglobin composition in pregnant women with thalassemia. clinicaltrials.gov/ct2/show/NCT02772016 (first received 13 May 2016). ">Li 2016</a>), and all five studies awaiting assessment (<a href="./references#CD013767-bbs2-0017" title="ChengYL , ZhangXH , SunYW , WangWJ , HuangJ , ChuNL , et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine2019;25(7):490-6. [PMID: 29761313]NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012). ">Cheng 2019</a>; <a href="./references#CD013767-bbs2-0018" title="HuangL , YaoHX . Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2016;24(3):806-9. [PMID: 27342514]">Huang 2016</a>; <a href="./references#CD013767-bbs2-0019" title="JainM , ChakrabartiP , DolaiTK , GhoshP , MandalPK , BaulSN , et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules &amp; Diseases2021;88:102544. [PMID: 33610115]">Jain 2021</a>; <a href="./references#CD013767-bbs2-0020" title="NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020). ">NCT04411082</a>; <a href="./references#CD013767-bbs2-0021" title="WuZK , LiuYM , ZhangXH , LiuWJ , LiM , WangRX . Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine)2007;5(2):137-40. [PMID: 17352867]">Wu 2007</a>). We tried twice or thrice; only one author from an included study responded, but without fully providing the requested (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). If data were not available, we would have described the level of attrition, attempted to explore whether there was any pattern associated with missing data and analyse the available data. Missing summary statistics, such as the standard deviation (SD), would be estimated by conversion of available statistics, such as the standard error (SE). We also attempted to establish whether the primary study used an intention‐to‐treat analysis (i.e. we analysed the participants in the groups to which they were randomised regardless of whether they received the allocated intervention). We tried contacting the study investigators for more information or any full reports if the included study was published in an abstract format or presented at meetings only (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> <p>We did not attempt to impute missing SDs.</p> </section> <section id="CD013767-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for heterogeneity between studies using the I² statistic and the Chi² test (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD013767-bbs2-0052" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We regarded heterogeneity as substantial if an I² value was greater than 80% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test. When we found that heterogeneity was too severe to meaningfully combine the studies, we did not perform a meta‐analysis. We noted a low P value (less than 0.10) in the Chi² test and interpret it in light of the number of included studies. We explored any heterogeneity by subgroup analysis. </p> </section> <section id="CD013767-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to minimise publication and reporting bias by conducting a comprehensive search. If we had obtained a sufficient numbers of studies (at least 10), we planned to assess publication bias by constructing and reviewing the symmetry of a funnel plot. If we had found any funnel plot asymmetry, we would have considered whether this could have been due to publication bias (<a href="./references#CD013767-bbs2-0083" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Page 2022</a>). Where reports were available, we compared the study protocols or methods sections with results presented in final study reports for any selective outcome reporting. </p> </section> <section id="CD013767-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Where studies were clinically and methodologically comparable, we performed meta‐analysis using a fixed‐effect model. We would have analysed rate ratio or time‐to‐event data using a generic inverse variance meta‐analysis. If no meta‐analysis was possible, or if we encountered substantial heterogeneity (as defined in <a href="#CD013767-sec-0033">Assessment of heterogeneity</a>), we reported a descriptive qualitative critical appraisal of the outcome information from these included studies (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> <p>If we had encountered any cross‐over studies, we would have included them and analysed them separately (<a href="./references#CD013767-bbs2-0044" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>), and followed the methods in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013767-bbs2-0054" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD013767-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We identified substantial clinical heterogeneity in our included studies and investigated it using the subgroup analyses as follows (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). Where meaningful, we carried out subgroup analysis for different types and combinations of HbF inducers. However, we were unable to conduct our other two preplanned subgroup analyses (type of NTDβT and baseline HbF proportion) in this review due to a lack of data. We plan to include these analyses in future updates of the review if the necessary data become available. </p> </section> <section id="CD013767-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to assess the robustness of our review results by repeating the analysis with the following adjustments, exclusion of studies with: </p> <p> <ol id="CD013767-list-0038"> <li> <p>unclear or high risk of bias regarding allocation concealment;</p> </li> <li> <p>unclear or high risk of bias regarding blinding of outcomes assessment;</p> </li> <li> <p>unclear or high risk of bias regarding completeness of follow‐up;</p> </li> <li> <p>high risk of selective outcome reporting.</p> </li> </ol> </p> <p>We also planned to use a sensitivity analysis to test the robustness of our choice of model used for meta‐analysis (<a href="./references#CD013767-bbs2-0040" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD013767-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used GRADE to reflect the certainty of evidence (<a href="./references#CD013767-bbs2-0099" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022a</a>) and used GRADEpro GDT software (<a href="./references#CD013767-bbs2-0050" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 7 March 2022. Available from gradepro.org.">GRADEpro GDT</a>) to create a summary of findings table for each comparison we presented, which had the following components: </p> <p> <ol id="CD013767-list-0039"> <li> <p>summarised key findings (participants, comparison and baseline information, outcome) (<a href="./references#CD013767-bbs2-0100" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>); </p> </li> <li> <p>summarised statistical results; and</p> </li> <li> <p>summarised certainty of evidence, magnitude of the effect including the source of any external information used in the 'Assumed risk' column or any departures from the standard methods, and reasons behind the decisions. </p> </li> </ol> </p> <p>We included the following outcomes in our summary of finding stables (<a href="./references#CD013767-bbs2-0100" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). </p> <p> <ol id="CD013767-list-0040"> <li> <p>Frequency of transfusion</p> </li> <li> <p>Transfusion‐free interval (post hoc change)</p> </li> <li> <p>Haemoglobin level (post hoc change)</p> </li> <li> <p>HbF level</p> </li> <li> <p>QoL</p> </li> <li> <p>Adverse events (iron overload, need for iron chelation, severe immunosuppression (e.g. requiring hospitalisation or cessation of the intervention or death) </p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013767-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013767-sec-0039"></div> <section id="CD013767-sec-0040"> <h3 class="title">Description of studies</h3> <p>For further details, see <a href="./references#CD013767-sec-0149" title="">Characteristics of included studies</a>; <a href="./references#CD013767-sec-0150" title="">Characteristics of excluded studies</a>; and <a href="./references#CD013767-sec-0151" title="">Characteristics of studies awaiting classification</a> tables. </p> <section id="CD013767-sec-0041"> <h4 class="title">Results of the search</h4> <p>Our search retrieved 1434 records of which 609 records were duplicates (<a href="#CD013767-fig-0001">Figure 1</a>). We excluded 795 records by title alone because none of them fit into our inclusion criteria, and assessed 29 records (21 studies) for eligibility. We proceeded to look for confirmatory evidence from the literature if the intervention had any HbF inducing properties: hydroxyurea (<a href="./references#CD013767-bbs2-0027" title="BaligaBS , PaceBS , ChenHH , ShahAK , YangYM . Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. American Journal of Hematology2000;65(3):227-33. [DOI: 10.1002/1096-8652(200011)65:3&amp;lt;227::aid-ajh9&amp;gt;3.0.co;2-v] [PMID: 11074540]">Baliga 2000</a>; <a href="./references#CD013767-bbs2-0097" title="RodriguezGI , KuhnJG , WeissGR , HilsenbeckSG , EckardtJR , ThurmanA , et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood1998;91(5):1533-41. [DOI: 10.1182/blood.V91.5.1533]">Rodriguez 1998</a>), HQK‐1001 (<a href="./references#CD013767-bbs2-0088" title="PerrineSP , WarginWA , BoosalisMS , WallisWJ , CaseS , KeeferJR , et al. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. Journal of Clinical Pharmacology2011;51(8):1186-94. [PMID: 21422239]">Perrine 2011</a>), thalidomide (<a href="./references#CD013767-bbs2-0022" title="AerbajinaiW , ZhuJ , GaoZ , ChinK , RodgersGP . Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood2007;110(8):2864-71. [DOI: 10.1182/blood-2007-01-065201] [PMID:17620452; PMCID: PMC2018668]">Aerbajinai 2007</a>), decitabine (5‐aza‐2'‐deoxycytidine) (<a href="./references#CD013767-bbs2-0087" title="PerrineSP , MillerBA , FallerDV , CohenRA , VichinskyEP , HurstD , et al. Sodium butyrate enhances fetal globin gene expression inerythroid progenitors of patients with Hb SS and beta thalassemia. Blood1989;74(1):454-9. [PMID: 2473801]">Perrine 1989</a>; <a href="./references#CD013767-bbs2-0057" title="KalantriSA , RayR , ChattopadhyayA , BhattacharjeeS , BiswasA , BhattacharyyaM . Efficacy of decitabine as haemoglobin F inducer in HbE/β-thalassemia. Annals of Hematology2018;97(9):1689-94. [DOI: 10.1007/s00277-018-3357-y]">Kalantri 2018</a>), l‐carnitine (<a href="./references#CD013767-bbs2-0086" title="PekalaJ , Patkowska-SokołaB , BodkowskiR , JamrozD , NowakowskiP , LochyńskiS , et al. L-carnitine – metabolic functions and meaning in humans life. Current Drug Metabolism2011;12(7):667-78. [DOI: 10.2174/138920011796504536] [PMID:21561431]">Pekala 2011</a>; <a href="./references#CD013767-bbs2-0087" title="PerrineSP , MillerBA , FallerDV , CohenRA , VichinskyEP , HurstD , et al. Sodium butyrate enhances fetal globin gene expression inerythroid progenitors of patients with Hb SS and beta thalassemia. Blood1989;74(1):454-9. [PMID: 2473801]">Perrine 1989</a>), Radix Astragali (the root of <i>Astragalus propinquus</i>) (<a href="./references#CD013767-bbs2-0067" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix Astragali stimulates p38MARK phosphorylation in pediatric patients with β-thalassemia. Evidence-Based Complementary and Alternative Medicine2016;2016:7468979. [DOI: 10.1155/2016/7468979] [PMID: 27882072; PMCID: PMC5110864]">Lu 2016</a>), resveratrol (<a href="./references#CD013767-bbs2-0042" title="DeSimoneJ , KoshyM , DornL , LavelleD , BresslerL , MolokieR , et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood2002;99(1):3905-8. [DOI: 10.1182/blood.v99.11.3905] [PMID: 12010787]">DeSimone 2002</a>), and YSSXG (<a href="./references#CD013767-bbs2-0045" title="FangS , WuZ , ZhangX , LiuY , WangW , ChaiL , et al. Clinical observation on YiSuiShengXue Granule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological &amp; Pharmaceutical Bulletin2007;30(11):2084-7. [DOI: 10.1248/bpb.30.2084] [PMID:17978480]">Fang 2007</a>). We finally included seven studies (13 records) in the review and excluded nine studies (10 records). We found five studies (six records) that we have listed as awaiting classification since we could not reach the authors for further clarification (<a href="./references#CD013767-bbs2-0019" title="JainM , ChakrabartiP , DolaiTK , GhoshP , MandalPK , BaulSN , et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules &amp; Diseases2021;88:102544. [PMID: 33610115]">Jain 2021</a>; <a href="./references#CD013767-bbs2-0020" title="NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020). ">NCT04411082</a>) or had other concerns (<a href="./references#CD013767-bbs2-0017" title="ChengYL , ZhangXH , SunYW , WangWJ , HuangJ , ChuNL , et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine2019;25(7):490-6. [PMID: 29761313]NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012). ">Cheng 2019</a>; <a href="./references#CD013767-bbs2-0021" title="WuZK , LiuYM , ZhangXH , LiuWJ , LiM , WangRX . Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine)2007;5(2):137-40. [PMID: 17352867]">Wu 2007</a>). One other study, <a href="./references#CD013767-bbs2-0018" title="HuangL , YaoHX . Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2016;24(3):806-9. [PMID: 27342514]">Huang 2016</a> replied that they would provide further information in the future. </p> <div class="figure" id="CD013767-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013767-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013767-sec-0042"> <h4 class="title">Included studies</h4> <p>We included seven studies (13 records) in this review (see <a href="./references#CD013767-sec-0149" title="">Characteristics of included studies</a> table). An overview of the main clinical characteristics of the included studies by type of HbF inducer is found in the table (<a href="#CD013767-tbl-0006">Table 2</a>). </p> <div class="table" id="CD013767-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies by foetal haemoglobin inducers</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age at enrolment (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of splenectomised participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dose and duration</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Single HbF inducer at any dose or duration compared with usual care or placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQK‐1001</p> <p>(oral tablet)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 17–45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sequential dose‐escalation</p> <p> <ol id="CD013767-list-0041"> <li> <p>from 10 mg/kg/day then to 30 mg/kg/day</p> </li> <li> <p>from 20 mg/kg/day then to 40 mg/kg/day</p> </li> </ol> </p> <p>56 intervention days with in between 8 weeks intervention‐free period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali</p> <p>(tea bag – oral drink)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CNP<sup>a</sup> </p> <p>(tea bag – oral drink)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Single HbF inducer at any dose or duration compared with another HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs decitabine</p> <p>(oral HU<sup>b</sup> vs subcutaneous) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily HU<sup>b</sup> </p> <p>Twice a week decitabine</p> <p>(no other details)</p> <p>Duration: 3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs thalidomide</p> <p>(appearance not stated. Both inducers were taken orally)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 6–45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 10 mg/kg/day</p> <p>Thalidomide: fixed‐dose 50 mg/day</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs resveratrol<sup>c</sup> </p> <p>(HU<sup>b</sup> vs capsule) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali vs CNP<sup>a</sup> </p> <p>(both in similar looking tea bag – oral drinks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>1 dose or dose regimen of an HbF inducer compared with another dose or dose regimen of the same HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs hydroxyurea</p> <p>(tablets)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 16.68, SD 6.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg/day vs 10 mg/kg/day</p> <p>Duration: 6 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>≥ 2 HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined resveratrol<sup>c</sup> and hydroxyurea vs hydroxyurea alone </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined resveratrol and hydroxyurea vs hydroxyurea alone</p> <p>(Resveratrol capsules, HU<sup>b</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined l‐carnitine and hydroxyurea vs hydroxyurea alone</p> <p>(L‐carnitine tablets, hydroxyurea capsules)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 4–35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60/120 participants</p> <p>(inclusive of groups on magnesium chloride)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>L‐carnitine: 50 mg/kg/day</p> <p>Duration: 6 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>CNP (combined natural preparation): combination of Radix Astragali (黄芪), <i>Codonopsis pilosula</i> (党参) and tortoise plastron (龟板).<br/><sup>b</sup>HU: unsure if the hydroxyurea was in the form of a capsule or tablet, but it was taken orally.<br/><sup>c</sup>Resveratrol: came in a form of a capsule that contained micronised trans‐resveratrol 500 mg and piperine 10 mg. Piperine was added to the capsule to increase the oral bioavailability of resveratrol. </p> </div> </div> <section id="CD013767-sec-0043"> <h5 class="title">Design</h5> <p>Of the seven included RCTs, one was a four‐arm study (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), two were three‐arm studies (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), and three were two‐arm studies (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). These studies were all of parallel design. The final study was a dose‐escalation RCT, where two cycles compared four different doses of an HbF inducer with placebo (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). Each cycle lasted 12 weeks (eight weeks of the intervention and four weeks of follow‐up), with a washout period of at least four weeks; participants were rerandomised for the second cycle. </p> <p>We did not identify any cross‐over studies. Two studies were phase 2 trials (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), one was a phase 3 trial (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>), but we are unsure about the remaining four studies. </p> </section> <section id="CD013767-sec-0044"> <h5 class="title">Sample sizes</h5> <p>Overall there were 373 participants with NTDβT included in the studies, of whom only 291 received interventions relevant to this review. The sample size of each study ranged from 21 participants (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>) to 61 participants (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> </section> <section id="CD013767-sec-0045"> <h5 class="title">Setting</h5> <p>The included studies were mainly conducted in Asia, the Middle East and North Africa. One was from China (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), three were from India (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>), and two were from Iran (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). One study had participants from South East Asia (Thailand) and the Middle East (Lebanon) (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <p>All studies were conducted in upper‐middle income countries except those from India, a lower‐middle income country (<a href="./references#CD013767-bbs2-0121" title="World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed prior to 7 March 2022).">World Bank 2021</a>). </p> </section> <section id="CD013767-sec-0046"> <h5 class="title">Study authors' declarations of interest</h5> <p>Four studies reported no conflict of interest (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). The remaining studies did not state this information (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> <section id="CD013767-sec-0047"> <h5 class="title">Sources of funding</h5> <p>Three studies received university or government funding (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), and one study was funded by a pharmaceutical company (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). The remaining studies did not report the source of funding (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> </section> <section id="CD013767-sec-0048"> <h5 class="title">Study dates</h5> <p>Five studies reported their study dates, which ranged from 2007 to 2017 (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). Two studies did not mention the study dates (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> </section> <section id="CD013767-sec-0049"> <h5 class="title">Participants</h5> <p>The participants had HbE/β‐thalassaemia with the phenotype of β‐thalassaemia intermedia (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>), a mixture of HbE/β‐thalassaemia and β<sup>+</sup>/β<sup>0</sup> thalassaemia (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>), β‐thalassaemia intermedia only (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), and β‐thalassaemia of mild to moderate severity (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>Some participants from two included studies are not considered in this review (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). In one study, there were 60 participants in two of the four treatment arms who did not use an HbF inducer (magnesium chloride) and were not relevant to this review (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). In the second study, 22 participants were transfusion‐dependent (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The studies reported these results separately from the NTDβT participants. </p> <p>The definitions of NTDβT were not consistent across all studies. Two studies considered participants to have NTDβT if they had a transfusion‐free interval of six months or more (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). One study defined NTDβT as at least three months transfusion‐free with the added criteria of no administration of haematinics for the past six months (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). One study defined NTDβT as "transfusion independent" despite participants persistently being in an anaemic state and potentially requiring intermittent transfusion during recurrent illnesses such as fever (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). The remaining three studies did not describe the frequency of participants' transfusions and described participants as "non‐transfusion‐dependent thalassaemia" or "not on regular transfusion" (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> <p>The age of the participants eligible for recruitment ranged from two years to 49 years. Four studies analysed a mixed population of children and adults with the mean age ranging from 13.76 (SD 9.05) years to 20.15 (SD 4.4) years (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>); none of these studies reported their results by age. Two studies included only adults whose mean age ranged from 28.2 (SD 5.6) to 33.9 (SD 8.2) years (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>); and one study only analysed children aged between two years and 18 years (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>Three studies enrolled some participants who had undergone splenectomy (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), while the other studies did not report this. One study also reviewed the spleen sizes as one of the pre‐ and postintervention outcomes (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). None of the studies performed a subgroup analysis between splenectomised and non‐splenectomised participants to look for any effect on the postintervention total haemoglobin. </p> </section> <section id="CD013767-sec-0050"> <h5 class="title">Interventions</h5> <p>The seven included studies tested eight different HbF inducers, four pharmacological and four natural in origin. The four pharmacological HbF inducers were hydroxyurea, HQK‐1001, thalidomide and decitabine. The four natural HbF inducers were resveratrol, l‐carnitine, Radix Astragali (黄芪) and a 3‐in‐1 herbal‐animal mixture that comprised Radix Astragali (黄芪), <i>Codonopsis pilosula</i> (党参) and tortoise plastron (龟板) in a tea bag. We referred to the 3‐in‐1 mixture as 'combined natural preparation' (CNP) in this review. Piperine capsules were to be taken together with resveratrol to increase the oral bioavailability of resveratrol. It is a natural substance with no HbF inducer properties or any effects on red cell stabilisation and production. </p> <p>Decitabine was given subcutaneously. Studies did not describe the appearances of the HQK‐1001 and thalidomide, but they were taken orally. The remaining inducers were taken orally, as tablets, capsules or a drink after immersing a tea bag that contained a mixture of natural ingredients in warm water. </p> </section> <section id="CD013767-sec-0051"> <h5 class="title">Comparisons</h5> <section id="CD013767-sec-0052"> <h6 class="title">Single foetal haemoglobin inducer versus placebo or usual care</h6> <p>Two studies (one of which had three arms) compared an HbF inducer against placebo or usual care (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The three‐arm study compared two different HbF inducers to placebo; we included both active arms in a single analysis by dividing the placebo group between the two intervention groups (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The comparisons were: </p> <p> <ol id="CD013767-list-0042"> <li> <p>HQK‐1001 at four different doses (10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg) versus placebo (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>); </p> </li> <li> <p>Radix Astragali versus placebo (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>); and </p> </li> <li> <p>CNP versus placebo (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </li> </ol> </p> <p>One study stated that the placebo was made to resemble the intervention in a tea bag (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), but the other study did not describe the placebo (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> <section id="CD013767-sec-0053"> <h6 class="title">Single foetal haemoglobin inducer versus another foetal haemoglobin inducer</h6> <p>Four studies compared a single HbF against a different HbF (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The comparisons were: </p> <p> <ol id="CD013767-list-0043"> <li> <p>hydroxyurea versus resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>); </p> </li> <li> <p>hydroxyurea versus thalidomide (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>); </p> </li> <li> <p>hydroxyurea versus decitabine (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>); and </p> </li> <li> <p>Radix Astragali versus CNP (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </li> </ol> </p> <p>The study comparing hydroxyurea to resveratrol had three arms and compared hydroxyurea plus placebo versus resveratrol plus placebo versus hydroxyurea plus resveratrol. This study was also eligible for the 'two or more HbF inducers versus a single HbF inducer, placebo or usual care' comparison (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </section> <section id="CD013767-sec-0054"> <h6 class="title">Comparing two different doses of the same foetal haemoglobin inducer</h6> <p>Two studies compared two or more different doses of the same HbF inducer (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <p>The first study compared hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). For this review, we considered the 20 mg/kg/day dose of hydroxyurea to be the intervention and the 10 mg/kg/day dose as the comparison (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> <p>The second study compared four different doses of HQK‐1001 against each other: 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> <section id="CD013767-sec-0055"> <h6 class="title">Two or more foetal haemoglobin inducers versus a single foetal haemoglobin inducer, placebo or usual care </h6> <p>Two studies compared a combination of HbF inducers against a single HbF inducer (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). The comparisons were: </p> <p> <ol id="CD013767-list-0044"> <li> <p>hydroxyurea plus resveratrol versus hydroxyurea plus placebo (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>); </p> </li> <li> <p>hydroxyurea plus resveratrol versus resveratrol plus placebo (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>); and </p> </li> <li> <p>hydroxyurea plus l‐carnitine versus hydroxyurea alone (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </li> </ol> </p> <p>Two studies compared a combination of two HbF inducers with a single HbF inducer (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). We included the single HbF inducer intervention arms of <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> in a single analysis by dividing the participants in the third arm, a combination treatment, between the two groups. In this study, the participants in resveratrol group were also given piperine capsules to increase the oral bioavailability of resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). The second study compared hydroxyurea plus l‐carnitine to hydroxyurea (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). This study did not use an HbF inducer in two out of its four arms (instead it used magnesium chloride), but given the potential effects of magnesium chloride on haemoglobin levels, we have only included the two arms using HbF inducer(s) in this review (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). Magnesium chloride may potentially sustain higher haemoglobin levels by stabilising the RBC membranes (<a href="./references#CD013767-bbs2-0115" title="WagnerCT , MartowiczML , LiveseySA , ConnorJ . Biochemical stabilization enhances red blood cell recovery and stability following cryopreservation. Cryobiology2002;45:153-66. [DOI: 10.1016/S0011-2240(02)00124-4]">Wagner 2002</a>); and since haemoglobin levels are used as the main determinant for a blood transfusion, we decided to only include the two study arms that used either hydroxyurea alone or a combination of hydroxyurea and l‐carnitine. </p> </section> <section id="CD013767-sec-0056"> <h6 class="title">Duration of intervention</h6> <p>The duration of the intervention ranged from two months (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>) to six months (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> </section> <section id="CD013767-sec-0057"> <h5 class="title">Outcomes</h5> <p>Three included studies had published protocols (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>No study reported on our primary outcome of frequency of blood transfusion or the transfusion‐free interval; however one study reported the transfusion units per participant per year, but we were unable to calculate a rate ratio (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). Three studies reported the number of participants who required a transfusion during the study (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>Four studies reported the mean haemoglobin levels before and after the intervention period over varying time points from six weeks up to six months (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). One study reported the median changes in total haemoglobin for at least eight weeks (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). One study reported the peak mean increment in total haemoglobin, increment range and % of participants with a rise in haemoglobin greater than 1.0 g/dL from baseline (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). The final study only reported the baseline median haemoglobin level and the number of participants who experienced a change from baseline (responders) (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). </p> <p>Two studies measured and reported absolute % HbF at specific time points (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>); one of these reported both HbF in grams per decilitre and % (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). One study reported % HbF as the change from baseline to the end of the intervention (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>), and two studies reported it as mean increment from baseline to end of therapy (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). One study reported mean % HbF at baseline, but not for any other time points (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). One study did not report % HbF (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> <p>No studies reported any long‐term sequelae of NTDβT such as growth, puberty and maxillary hyperplasia; although one study did measure pulmonary hypertension and spleen size before and after the intervention (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>No studies used a validated QoL measuring tool; however, one study measured improvement in energy level and sense of well‐being (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> <p>No studies reported the adverse outcomes of iron overload or the need for iron chelation. All seven studies reported adverse drug effects (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). Two studies reported that they would look for adverse effects, but did not specify any in particular (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). Five studies prespecified the adverse effects they would measure, but none of these studies included any of our prespecified adverse effects. One study measured neutropenia, thrombocytopenia, gastrointestinal disturbances and raised liver enzymes (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). One study used the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) scoring to assess the severity of adverse events (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). One study reported infections, cytopenia and deranged biochemical parameters (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). One study reported adverse effects of the drug on the liver and kidneys (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), and one study measured white cell counts, neutrophil counts and platelet counts, liver function tests (alanine transaminase (ALT), aspartate aminotransferase (AST), gamma‐glutamyl transferase (GGT)) and renal profiles (urea, sodium, potassium, creatinine) (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>More details are presented in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </section> </section> <section id="CD013767-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded nine studies (10 records) (<a href="./references#CD013767-bbs2-0008" title="BiswasS , ChaudhuriS , KumarM , SenA , BhattyacharyyaM , GhoshK . The role of hydroxyurea and valproic acid in the management of severe HbE- β thalassaemia. Indian Journal of Hematology and Blood Transfusion2014;30(Suppl 2):S505. [CFGD REGISTER: TH144] ">Biswas 2014</a>; <a href="./references#CD013767-bbs2-0009" title="ChaiLM , WuZK , ZhangXH , CaiH . Effect of yisuishengxue granule on gene expression in children with beta-thalassemia. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):591-4. [ISSN 1003-5370]">Chai 2005</a>; <a href="./references#CD013767-bbs2-0010" title="ChengYL , ZhangXH , SunYW , WangWJ , FangSP , WuZK . Clinical effect and mechanism of Yisui Shengxue granules in thalassemia patients with mild, moderate, or severe anemia. Evidence-based Complementary Alternative Medicine2016;2016:1713897. [DOI: 10.11155/2016/1713897]">Cheng 2016</a>; <a href="./references#CD013767-bbs2-0011" title="ElalfyMS , AdlyAA , IsmailEA , ElhenawyYI , ElghamryIR . Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. European Journal of Haematology2013;91(6):522-33. [PMID: 23927461]">Elalfy 2013</a>; <a href="./references#CD013767-bbs2-0012" title="FangS , WuZ , ZhangX , LiuY , WangW , ChaiL , et al. Clinical observation on YiSuiShengXue Granule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological &amp; Pharmaceutical Bulletin2007;30(11):2084-7. [DOI: 10.11248/bpb.30.2084]">Fang 2007</a>; <a href="./references#CD013767-bbs2-0013" title="GuoL , QianX , ZhaoD , LuZ , ChenJ , WuQ , et al. Radix astragali induces in vitro and in vivo synthesis of fetal hemoglobin in non‑transfusion‑dependent β‑thalassemia: a preliminary study. Molecular Medicine Reports2014;Withdrawn. [DOI: 10.3892/mmr.2014.2856] [TRIAL ID: ChiCTR-TRC-13003672]">Guo 2014</a>; <a href="./references#CD013767-bbs2-0014" title="LiY , HeH , YangL , LiX , LiD , LuoS . Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia. International Journal of Hematology2016;104(5):559-65. [PMID: 27456464]NCT02772016. Therapeutic effect of colla corii asini on improving anemia and hemoglobin composition in pregnant women with thalassemia. clinicaltrials.gov/ct2/show/NCT02772016 (first received 13 May 2016). ">Li 2016</a>; <a href="./references#CD013767-bbs2-0015" title="LoukopoulosD , VoskaridouE , StamoulakatouA , PapassotiriouY , KalotychouV , LoutradiA , et al. Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences1998;850(1):120-8. [DOI: 10.1111/j.1749-6632.1998.tb10469.x] [PMID: 9668534]">Loukopoulos 1998</a>; <a href="./references#CD013767-bbs2-0016" title="PatthamalaiP , FuchareonS , ChaneiamN , GhalieRG , ChuiDH , BoosalisMS , et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood2014;123(12):1956-7. [DOI: 10.1182/blood-2013-11-538470]">Patthamalai 2014</a>). </p> <p>Four studies (four records) were not RCTs (<a href="./references#CD013767-bbs2-0009" title="ChaiLM , WuZK , ZhangXH , CaiH . Effect of yisuishengxue granule on gene expression in children with beta-thalassemia. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):591-4. [ISSN 1003-5370]">Chai 2005</a>; <a href="./references#CD013767-bbs2-0010" title="ChengYL , ZhangXH , SunYW , WangWJ , FangSP , WuZK . Clinical effect and mechanism of Yisui Shengxue granules in thalassemia patients with mild, moderate, or severe anemia. Evidence-based Complementary Alternative Medicine2016;2016:1713897. [DOI: 10.11155/2016/1713897]">Cheng 2016</a>; <a href="./references#CD013767-bbs2-0015" title="LoukopoulosD , VoskaridouE , StamoulakatouA , PapassotiriouY , KalotychouV , LoutradiA , et al. Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences1998;850(1):120-8. [DOI: 10.1111/j.1749-6632.1998.tb10469.x] [PMID: 9668534]">Loukopoulos 1998</a>; <a href="./references#CD013767-bbs2-0016" title="PatthamalaiP , FuchareonS , ChaneiamN , GhalieRG , ChuiDH , BoosalisMS , et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood2014;123(12):1956-7. [DOI: 10.1182/blood-2013-11-538470]">Patthamalai 2014</a>), and one study (one record) was withdrawn after publication (<a href="./references#CD013767-bbs2-0013" title="GuoL , QianX , ZhaoD , LuZ , ChenJ , WuQ , et al. Radix astragali induces in vitro and in vivo synthesis of fetal hemoglobin in non‑transfusion‑dependent β‑thalassemia: a preliminary study. Molecular Medicine Reports2014;Withdrawn. [DOI: 10.3892/mmr.2014.2856] [TRIAL ID: ChiCTR-TRC-13003672]">Guo 2014</a>). </p> <p>The excluded studies used either intervention that are considered RBC stabilisers (magnesium chloride) or RBC enhancers without any effect on HbF production (erythropoietin, <i>colla corii asini</i>). We excluded one RCT (one record) that included a co‐intervention (human erythropoietin), which we did not consider an HbF inducer (<a href="./references#CD013767-bbs2-0011" title="ElalfyMS , AdlyAA , IsmailEA , ElhenawyYI , ElghamryIR . Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. European Journal of Haematology2013;91(6):522-33. [PMID: 23927461]">Elalfy 2013</a>). We excluded one RCT (two records) that used <i>colla corii asini</i>, a bone marrow erythrocyte progenitor cells activator that improves anaemia but reduces HbF and HbA<sub>2</sub> levels (<a href="./references#CD013767-bbs2-0014" title="LiY , HeH , YangL , LiX , LiD , LuoS . Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia. International Journal of Hematology2016;104(5):559-65. [PMID: 27456464]NCT02772016. Therapeutic effect of colla corii asini on improving anemia and hemoglobin composition in pregnant women with thalassemia. clinicaltrials.gov/ct2/show/NCT02772016 (first received 13 May 2016). ">Li 2016</a>). </p> <p>The remaining two excluded studies enrolled participants with transfusion‐dependent HbE/β‐thalassaemia or β‐thalassaemia major, but used HbF inducers (hydroxyurea, Radix Astragali, YSSXG) as their interventions (<a href="./references#CD013767-bbs2-0008" title="BiswasS , ChaudhuriS , KumarM , SenA , BhattyacharyyaM , GhoshK . The role of hydroxyurea and valproic acid in the management of severe HbE- β thalassaemia. Indian Journal of Hematology and Blood Transfusion2014;30(Suppl 2):S505. [CFGD REGISTER: TH144] ">Biswas 2014</a>; <a href="./references#CD013767-bbs2-0012" title="FangS , WuZ , ZhangX , LiuY , WangW , ChaiL , et al. Clinical observation on YiSuiShengXue Granule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological &amp; Pharmaceutical Bulletin2007;30(11):2084-7. [DOI: 10.11248/bpb.30.2084]">Fang 2007</a>). </p> <p>The intervention used in the attempt to increase the haemoglobin levels or reduce the severity of anaemia differed between the studies. Details of these excluded trials can be found in the <a href="./references#CD013767-sec-0150" title="">Characteristics of excluded studies</a> table and <a href="./appendices#CD013767-sec-0139">Appendix 2</a>. </p> <section id="CD013767-sec-0059"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> <section id="CD013767-sec-0060"> <h5 class="title">Studies awaiting classification</h5> <p>Five studies are awaiting classification (<a href="./references#CD013767-bbs2-0017" title="ChengYL , ZhangXH , SunYW , WangWJ , HuangJ , ChuNL , et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine2019;25(7):490-6. [PMID: 29761313]NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012). ">Cheng 2019</a>; <a href="./references#CD013767-bbs2-0018" title="HuangL , YaoHX . Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2016;24(3):806-9. [PMID: 27342514]">Huang 2016</a>; <a href="./references#CD013767-bbs2-0019" title="JainM , ChakrabartiP , DolaiTK , GhoshP , MandalPK , BaulSN , et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules &amp; Diseases2021;88:102544. [PMID: 33610115]">Jain 2021</a>; <a href="./references#CD013767-bbs2-0020" title="NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020). ">NCT04411082</a>; <a href="./references#CD013767-bbs2-0021" title="WuZK , LiuYM , ZhangXH , LiuWJ , LiM , WangRX . Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine)2007;5(2):137-40. [PMID: 17352867]">Wu 2007</a>). We are waiting further information from the authors of two of these (<a href="./references#CD013767-bbs2-0019" title="JainM , ChakrabartiP , DolaiTK , GhoshP , MandalPK , BaulSN , et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules &amp; Diseases2021;88:102544. [PMID: 33610115]">Jain 2021</a>; <a href="./references#CD013767-bbs2-0020" title="NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020). ">NCT04411082</a>). We are currently waiting for further information from the authors of one study (<a href="./references#CD013767-bbs2-0018" title="HuangL , YaoHX . Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2016;24(3):806-9. [PMID: 27342514]">Huang 2016</a>). We are currently attempting to verify the data from the remaining two studies (<a href="./references#CD013767-bbs2-0017" title="ChengYL , ZhangXH , SunYW , WangWJ , HuangJ , ChuNL , et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine2019;25(7):490-6. [PMID: 29761313]NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012). ">Cheng 2019</a>; <a href="./references#CD013767-bbs2-0021" title="WuZK , LiuYM , ZhangXH , LiuWJ , LiM , WangRX . Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine)2007;5(2):137-40. [PMID: 17352867]">Wu 2007</a>). Further details of these studies can be found in the <a href="./references#CD013767-sec-0151" title="">Characteristics of studies awaiting classification</a> table. </p> </section> </section> </section> <section id="CD013767-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of the risk of bias assessment for each included study are presented in the <a href="./references#CD013767-sec-0149" title="">Characteristics of included studies</a> table and summary descriptions of the assessments are presented in <a href="#CD013767-fig-0002">Figure 2</a> and <a href="#CD013767-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013767-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD013767-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD013767-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013767-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013767-sec-0062"> <h4 class="title">Allocation</h4> <section id="CD013767-sec-0063"> <h5 class="title">Sequence generation</h5> <p>We judged four studies at low risk of bias for sequence generation because they described a random component in the sequence generation process such as using random number table, using computer‐generated random numbers and random numbers generated via a numbering software (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We judged three studies at unclear risk of bias for sequence generation because they did not adequately describe how sequence generation was accomplished (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> <section id="CD013767-sec-0064"> <h5 class="title">Allocation concealment</h5> <p>We judged all studies at unclear risk of bias for allocation concealment. None reported whether the allocation was concealed or how it was done (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> </section> <section id="CD013767-sec-0065"> <h4 class="title">Blinding</h4> <section id="CD013767-sec-0066"> <h5 class="title">Performance bias (blinding of participants and personnel)</h5> <p>We judged three studies at high risk of performance bias (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> provided no information on how hydroxyurea and thalidomide were designed to be as similar as possible in terms of appearance, smell, taste and frequency of administration. In <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>, the intervention and comparator were distinguishable by mode of administration and possibly appearance; hydroxyurea was given orally, but decitabine was given subcutaneously. In <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>, there were differences in the frequency of administration and appearance; hydroxyurea was given once a day while l‐carnitine was given more than once a day. </p> <p>We judged three studies at unclear risk of performance bias (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). <a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a> did not report the blinding of the participants and personnel for all outcomes. <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> did not describe the placebo. In <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>, it may have been possible to distinguish the intervention from placebo through taste and smell, although both were made to look similar and were administered similarly. </p> <p>We judged the remaining study at low risk of performance bias as the study used a matching placebo to ensure proper blinding of participants and personnel (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> <section id="CD013767-sec-0067"> <h5 class="title">Detection bias (blinding of outcome assessments)</h5> <p>We assessed detection bias separately for objective and subjective outcomes. We judged haemoglobin and HbF levels to be objective and unlikely to be affected by lack of blinding. We judged blood transfusion, long‐term sequelae, QoL and adverse events to be subjective and hence at high risk of detection bias where there was a lack of blinding. </p> <section id="CD013767-sec-0068"> <h6 class="title">Objective outcomes</h6> <p>We judged all studies to have low risk of detection bias for haemoglobin levels and HbF because these outcomes were laboratory assessments, judged not to influence response to interventions (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> <section id="CD013767-sec-0069"> <h6 class="title">Subjective outcomes</h6> <p>Four studies reported on blood transfusion. We judged two studies to have high risk of detection bias because the blinding was not possible (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>), and two studies to have an unclear risk because the blinding of the outcome assessors was either not reported or could not be determined (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> <p>Only one study reported long‐term sequelae and was at high risk of bias because blinding was not possible and the measurements (splenic size and pulmonary echocardiogram findings) were operator‐dependent (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>Only one study assessed QoL and was at unclear risk of bias because it was unclear whether the participants were blinded, and they were the ones who reported any changes in energy level and sense of well‐being (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> <p>For adverse events, we judged one study to have low risk of detection bias because the adverse events reported were based on laboratory measurements (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We judged three studies at high risk of detection bias because blinding was not possible and the participants were the ones who reported the adverse events (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). We judged three studies at unclear risk of detection bias because the blinding of outcome assessors was unclear and the adverse events reported depended on the clinical judgement or participants' perceptions, or both (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </section> </section> </section> <section id="CD013767-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four studies to have low risk of attrition bias because all enrolled participants including dropouts (if any) were analysed at the end of the study and they were analysed in the group to which they were assigned (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We judged one study at high risk of attrition bias because it did not analyse all the recruited participants (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). We judged two studies at unclear risk of attrition bias because they were abstracts and there were no details on the numbers of participants enrolled or who withdrew (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> </section> <section id="CD013767-sec-0071"> <h4 class="title">Selective reporting</h4> <p>We judged three studies at low risk of reporting bias because they reported all expected outcomes (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We judged one study at high risk of reporting bias because the methods section reported participants to have undergone an interview regarding their sense of well‐being but did not report the result of this interview (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). We judged three studies at unclear risk of reporting bias (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). Two studies were abstracts with limited information (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>), and one study did not clearly state the time point of measurement for HbF level and reported only baseline HbF (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> <section id="CD013767-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>We judged six studies at low risk of other bias (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We judged one study to have unclear risk of bias because we were unclear about the washout period (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> </section> <section id="CD013767-sec-0073"> <h3 class="title" id="CD013767-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD013767-tbl-0001"><b>Summary of findings 1</b> Single foetal haemoglobin inducer at any dose or duration compared with usual care or placebo</a>; <a href="./full#CD013767-tbl-0003"><b>Summary of findings 2</b> Single foetal haemoglobin inducer at any dose or duration compared with another foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</a>; <a href="./full#CD013767-tbl-0004"><b>Summary of findings 3</b> One dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</a>; <a href="./full#CD013767-tbl-0005"><b>Summary of findings 4</b> Two or more foetal haemoglobin inducers at any dose or duration compared with a usual management protocol, placebo or a single foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</a> </p> <section id="CD013767-sec-0074"> <h4 class="title">A single foetal haemoglobin inducer versus usual care or placebo</h4> <p>See <a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>. </p> <p>Two studies compared an HbF inducer with placebo (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). One assessed HQK‐1001 given by sequential dose‐escalation with a washout period between doses (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>); one compared Radix Astragali versus CNP versus placebo (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <section id="CD013767-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD013767-sec-0076"> <h6 class="title">1. Blood transfusion</h6> <p>Neither study reported any results for frequency of transfusion measured by transfused volume per year or transfusion‐free interval (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> <section id="CD013767-sec-0077"> <h6 class="title">2. Haemoglobin</h6> <p>One study reported haemoglobin at three months postintervention (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). Since this was a three‐arm study where two different types of HbF inducers were compared against a placebo control group, we made a judgement to split the controls into almost equal numbers when we meta‐analysed the three arms (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The point estimates for the two different HbF inducers compared to placebo favoured HbF inducers (MD 1.33 g/dL, 95% CI 0.54 to 2.11; 1 study, 35 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0004" title="">Analysis 1.1</a>). We downgraded the certainty of the evidence by one level for indirectness because the follow‐up duration was short and insufficient to identify potential changes and two levels for imprecision because the conclusion was based on a very small sample size (<a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>). </p> <p>One study (21 participants) comparing four different doses of HQK‐1001 with placebo reported that there was no difference in median haemoglobin for any dose compared with placebo at 12 weeks (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> </section> <section id="CD013767-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD013767-sec-0079"> <h6 class="title">1. Foetal haemoglobin (%)</h6> <p>One study reported HbF at three months postintervention (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). For the meta‐analysis we split the number of participants in the control group into almost equal portions, one for each intervention. There may be an increase in HbF for both HbF inducers compared with placebo (MD 12.00%, 95% CI −0.74% to 24.75%; 1 study, 35 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0005" title="">Analysis 1.2</a>). We downgraded the certainty of the evidence one level for indirectness because the follow‐up duration was short and insufficient to identify potential changes and two levels for imprecision because optimal sample size was not achieved and there were wide CIs that included both appreciable benefit and appreciable harm. </p> <p>In the second study, investigators reported an increase in median HbF at 12 weeks only with one of the four doses, the HQK‐1001 20 mg/kg/dose, when compared with placebo; data were presented without a measure of dispersion (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> <section id="CD013767-sec-0080"> <h6 class="title">2. Long‐term sequelae of non‐transfusion‐dependent β‐thalassaemia</h6> <p>Neither study reported long‐term sequelae of NTDβT in terms of changes to growth, puberty, extramedullary haematopoiesis and maxillary hyperplasia. </p> </section> <section id="CD013767-sec-0081"> <h6 class="title">3. Quality of life</h6> <p>Neither study reported QoL.</p> </section> <section id="CD013767-sec-0082"> <h6 class="title">4. Adverse outcomes</h6> <section id="CD013767-sec-0083"> <p><b>a. Iron overload</b></p> <p>Neither study reported QoL.</p> </section> <section id="CD013767-sec-0084"> <p><b>b. Need for iron chelation</b></p> <p>Neither study reported the need for iron chelation.</p> </section> <section id="CD013767-sec-0085"> <p><b>c. Adverse drug effects</b></p> <p><a href="./full#CD013767-tbl-0002">Table 1</a> provides an overall summary of the prespecified adverse effects, reported adverse effects and adverse effects that were not reported in the included studies. </p> <p>In one study, the five most common adverse drug effects reported in the HQK‐1001 10 mg/kg group were upper respiratory tract infection, headache, fatigue, nausea and dizziness; other effects reported were fever, palpitations, suprapubic pain, gastritis, gastroenteritis, upper abdominal pain, back pain and severe upper respiratory tract infection (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). Nausea, vomiting and abdominal pain occurred more frequently among the HQK‐1001 20 mg/kg and 40 mg/kg groups, and fatigue occurred more frequently among the HQK‐1001 40 mg/kg group. There were severe adverse effects, namely upper abdominal pain, gastritis, suprapubic pain and back pain, in each dose of HQK‐1001. Headache and gastroenteritis occurred in the placebo group. There were too few events to be able to assess whether higher doses were associated with more adverse effects or whether there were more adverse effects in the HQK‐1001 or placebo groups (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). More details about the adverse events for each dose of HQK‐1001 are in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> <p>None of the adverse drug effects prespecified by the second study occurred (abnormalities in blood counts, liver enzyme levels and renal profile) (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>The certainty of evidence was very low for all studies for adverse drug effects. We downgraded one level for indirectness because the follow‐up duration was short and insufficient to see changes and two levels for imprecision because of the very small sample size well below the optimal sample size (<a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> </section> </section> <section id="CD013767-sec-0086"> <h4 class="title">A single foetal haemoglobin inducer at any dose compared with another foetal haemoglobin inducer </h4> <p>See <a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>. </p> <p>Four studies compared a single HbF inducer with another HbF inducer (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>The comparisons were:</p> <p> <ol id="CD013767-list-0045"> <li> <p>hydroxyurea versus thalidomide (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>); </p> </li> <li> <p>hydroxyurea versus decitabine (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>); </p> </li> <li> <p>Radix Astragali versus CNP (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>); and </p> </li> <li> <p>hydroxyurea versus resveratrol – participants from both groups also received a placebo (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </li> </ol> </p> <section id="CD013767-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD013767-sec-0088"> <h6 class="title">1. Blood transfusion</h6> <p>None of the studies reported frequency of transfusion in terms of transfused volume per year or transfusion‐free interval. </p> <p>One study reported that there was a significant reduction in transfusion for thalidomide compared with hydroxyurea (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). There was a mean of 3 units/participant/year (range 1 unit/participant/year to 6 units/participant/year) transfused at six months postintervention for the hydroxyurea group (15 participants) but none for the thalidomide group (15 participants). The study did not report SDs and we could not contact the authors for further information. The certainty of evidence was very low; downgraded one level for lack of blinding and two levels for imprecision because conclusions were based on one small study with very little information. </p> <p>A second study reported three participants required blood transfusion within a six‐month intervention period, one from the resveratrol group and two from the hydroxyurea group (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </section> <section id="CD013767-sec-0089"> <h6 class="title">2. Haemoglobin</h6> <p>All four studies reported haemoglobin at different time points using different comparisons (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>In one study, at three months mean haemoglobin was lower in the Radix Astragali group compared to the CNP group (MD −0.50 g/dL, 95% CI −1.38 to 0.38; 24 participants; low‐certainty evidence; <a href="./references#CD013767-fig-0006" title="">Analysis 2.1</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). In one study, at six months mean haemoglobin was lower in the hydroxyurea group when compared to resveratrol (MD −0.30 g/dL, 95% CI −1.14 to 0.54; 34 participants; low‐certainty evidence; <a href="./references#CD013767-fig-0006" title="">Analysis 2.1</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). We downgraded both analyses twice for imprecision because findings were based on one small study and the CIs included both appreciable benefit and appreciable harm (<a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>). </p> <p>Two studies reported results we were unable to analyse. One study reported that the peak increase in haemoglobin in the hydroxyurea group was 0.98 g/dL (range 0.1 g/dL to 1.4 g/dL) and in the decitabine group was 1.28 g/dL (range 0.5 g/dL to 1.6 g/dL), but the time point for this observation was not stated (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). One study stated narratively that there was a significant increase in haemoglobin at one, three and six months postintervention in the thalidomide group compared to the hydroxyurea group (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). </p> </section> </section> <section id="CD013767-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD013767-sec-0091"> <h6 class="title">1. Foetal haemoglobin (%)</h6> <p>Three studies reported HbF at three months (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>) and six months (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) postintervention. </p> <p>At three months, there was no difference in mean HbF between the CNP and Radix Astragali groups (MD 5.00%, 95% CI −11.44% to 21.44%; 1 study, 24 participants; low‐certainty evidence; <a href="./references#CD013767-fig-0007" title="">Analysis 2.2</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). We downgraded the certainty of the evidence twice for imprecision because findings were based on one small trial with very wide CIs (<a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>). </p> <p>At six months, there was no difference in mean HbF between thalidomide and hydroxyurea (MD 3.50%, 95% CI −1.41% to 8.41%; 1 study; 30 participants; low‐certainty evidence; <a href="./references#CD013767-fig-0007" title="">Analysis 2.2</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). We downgraded twice for imprecision because findings were based on one small trial with very wide CIs (<a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>). </p> <p>At six months, one study reported a mean increase in HbF of 5.13% in the hydroxyurea group and 5.38% in the decitabine group (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). There was no measure of dispersion and attempts to contact the authors were unsuccessful. </p> </section> <section id="CD013767-sec-0092"> <h6 class="title">2. Long‐term sequelae of non‐transfusion‐dependent β‐thalassaemia</h6> <p>None of the studies reported growth, puberty, maxillary hyperplasia and severity of extramedullary haematopoiesis (liver and spleen size). </p> </section> <section id="CD013767-sec-0093"> <h6 class="title">3. Quality of life</h6> <p>None of the studies reported QoL.</p> </section> <section id="CD013767-sec-0094"> <h6 class="title">4. Adverse outcomes</h6> <section id="CD013767-sec-0095"> <p><b>a. Iron overload</b></p> <p>One study reported the baseline ferritin level, but did not report the effect of the intervention on this outcome (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </section> <section id="CD013767-sec-0096"> <p><b>b. Need for iron chelation</b></p> <p>None of the studies reported the need for iron chelation.</p> </section> <section id="CD013767-sec-0097"> <p><b>c. Adverse drug effects</b></p> <p>We present an overall summary of the prespecified adverse effects, reported adverse effects and adverse effects that were not reported in the included studies in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> <p>Two studies prespecified adverse drug effects for each HbF inducer and reported the frequency of the observed events (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>), and two studies prespecified and reported the types of adverse drug effects without the frequency (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). The certainty of evidence was very low for all studies in this comparison. We downgraded one level for lack of blinding and two levels for imprecision because findings were based on one small study with a very small sample size (<a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>). </p> <p>Hydroxyurea </p> <p>One study reported mild gastrointestinal upset (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>), while one study reported a respiratory tract infection, neurological problems and fever (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> <p>Thalidomide </p> <p>One study reported somnolence and headache (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>). </p> <p>Decitabine </p> <p>One study reported a respiratory tract infection (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>). </p> <p>Resveratrol </p> <p>One study reported gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea, gastrointestinal bleeding, headache and malaise (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> <p>Radix Astragali </p> <p>One study reported that none of the prespecified adverse drug effects (abnormalities in blood counts, liver enzyme levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>Combined natural preparation </p> <p>One study reported that none of the prespecified adverse drug effects (abnormalities in blood counts, liver enzyme levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> </section> </section> </section> <section id="CD013767-sec-0098"> <h4 class="title">A single dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer </h4> <p>See <a href="./full#CD013767-tbl-0004">summary of findings Table 3</a>. </p> <p>Two studies compared different doses of the same HbF inducer (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <p>One trial involving 61 participants compared hydroxyurea 10 mg/kg/day against hydroxyurea 20 mg/kg/day (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>) and one trial involving 21 participants included four different doses of HQK‐1001 (10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day and 40 mg/kg/day) (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <section id="CD013767-sec-0099"> <h5 class="title">Primary outcomes</h5> <section id="CD013767-sec-0100"> <h6 class="title">1. Blood transfusion</h6> <p>Neither study presented their results as frequency of transfusion measured by transfused volume per year or transfusion‐free interval. </p> <p>However, one study reported that 7/29 participants in the hydroxyurea 20 mg/kg/day group and 0/32 participants in the hydroxyurea 10 mg/kg/day group required a blood transfusion during the six‐month intervention (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> </section> <section id="CD013767-sec-0101"> <h6 class="title">2. Haemoglobin</h6> <p>One study reported that mean haemoglobin was lower in the hydroxyurea 20 mg/kg/day group at 6, 12 and 24 weeks (24 weeks: MD −2.39 g/dL, 95% CI −2.80 to −1.98; 61 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0008" title="">Analysis 3.1</a>; <a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). We downgraded the certainty of the evidence by one level for risk of bias because allocation concealment was unclear and two levels for imprecision because findings were based on one small study with a very small sample size (<a href="./full#CD013767-tbl-0004">summary of findings Table 3</a>). </p> <p>One study presented the haemoglobin measurements graphically as medians without a measure of dispersion and did not compare the four different doses of HQK‐1001 with each (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> </section> <section id="CD013767-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD013767-sec-0103"> <h6 class="title">1. Foetal haemoglobin</h6> <p>One study reported that at 24 weeks, the mean HbF was lower in the hydroxyurea 20 mg/kg/day group compared with hydroxyurea 10 mg/kg/day (MD −10.20%, 95% CI −16.28% to −4.12%; 61 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0009" title="">Analysis 3.2</a>; <a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). We downgraded one level for risk of bias because the concealment of allocation was unclear and two levels for imprecision because findings were based on one small study with a very small information size (<a href="./full#CD013767-tbl-0004">summary of findings Table 3</a>). </p> </section> <section id="CD013767-sec-0104"> <h6 class="title">2. Long‐term sequelae of non‐transfusion‐dependent β‐thalassaemia</h6> <p>Neither study reported long‐term sequelae (growth, puberty, maxillary hyperplasia and severity of extra‐medullary haematopoiesis). </p> </section> <section id="CD013767-sec-0105"> <h6 class="title">3. Quality of life</h6> <p>Neither study reported QoL. The study of hydroxyurea prespecified that 'sense of well‐being' and 'state of energy' would be measured, but these outcomes were not reported (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> </section> <section id="CD013767-sec-0106"> <h6 class="title">4. Adverse outcomes</h6> <section id="CD013767-sec-0107"> <p><b>a. Iron overload</b></p> <p>Neither study reported iron overload.</p> </section> <section id="CD013767-sec-0108"> <p><b>b. Need for iron chelation</b></p> <p>Neither study reported the need for iron chelation.</p> </section> <section id="CD013767-sec-0109"> <p><b>c. Adverse drug effects</b></p> <p>We present an overall summary of the prespecified adverse effects, reported adverse effects and adverse effects that were not reported in the included studies in <a href="./full#CD013767-tbl-0002">Table 1</a>. Both studies in this comparison prespecified the adverse effects of the inducer being compared. </p> <p>One study reported found a higher risk of neutropenia (defined by the authors as absolute neutrophil count below 0.5 × 10<sup>3</sup>/μL) in the hydroxyurea 20 mg/kg/day group (RR 9.93, 95% CI 1.34 to 73.67; 61 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0010" title="">Analysis 3.3</a>; <a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). This study also found a higher risk of thrombocytopenia (defined as a platelet count below 50 × 10<sup>3</sup>/μL) in the hydroxyurea 20 mg/kg/day group (RR 3.68, 95% CI 1.12 to 12.07; 61 participants; very low‐certainty evidence; <a href="./references#CD013767-fig-0010" title="">Analysis 3.3</a>). We downgraded both analyses one level for indirectness because the duration of the intervention was short and insufficient to identify potential changes and two levels for imprecision because findings were based on one small study with very wide CIs (<a href="./full#CD013767-tbl-0004">summary of findings Table 3</a>). </p> <p>The adverse drug effects reported by the HQK‐1001 study are presented in the first comparison 'Single HbF inducer versus usual care or placebo' (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> </section> </section> </section> </section> <section id="CD013767-sec-0110"> <h4 class="title">Two or more foetal haemoglobin inducers at any dose or duration compared with a usual care, placebo or a single foetal haemoglobin inducer </h4> <p>See <a href="./full#CD013767-tbl-0005">summary of findings Table 4</a>. </p> <p>Two studies compared a combination of two HbF inducers with a single HbF inducer (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>The comparisons were:</p> <p> <ol id="CD013767-list-0046"> <li> <p>hydroxyurea plus placebo versus hydroxyurea plus resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>); </p> </li> <li> <p>hydroxyurea versus hydroxyurea plus l‐carnitine (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>); and </p> </li> <li> <p>resveratrol plus placebo versus hydroxyurea plus resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> </li> </ol> </p> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> gave no details about the placebo used alongside the single HbF inducers. Furthermore, the participants in resveratrol group were also given piperine capsules to increase the oral bioavailability of resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). </p> <p>No studies compared a combination of two or more HbF inducers against a placebo or usual care. </p> <section id="CD013767-sec-0111"> <h5 class="title">Primary outcomes</h5> <section id="CD013767-sec-0112"> <h6 class="title">1. Blood transfusion</h6> <p>Neither study presented their results as frequency of transfusion measured by transfused volume per year or transfusion‐free interval. </p> <p>The study comparing hydroxyurea to hydroxyurea plus l‐carnitine (120 participants) reported that 10 participants needed a blood transfusion within the six‐month intervention period, but did not specify which intervention they had received (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> <section id="CD013767-sec-0113"> <h6 class="title">2. Haemoglobin</h6> <p>One study reported haemoglobin at six months postintervention (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). Haemoglobin levels were lower in the group with resveratrol plus hydroxyurea compared to one of the study's HbF inducers (either resveratrol alone or hydroxyurea alone) (MD −0.74 g/dL, 95% CI −1.45 to −0.03; 54 participants; low‐certainty evidence; <a href="./references#CD013767-fig-0011" title="">Analysis 4.1</a>). We downgraded the certainty of the evidence by two levels for imprecision because findings were based on one small trial with a very small information size (<a href="./full#CD013767-tbl-0005">summary of findings Table 4</a>). </p> <p>One study reported an increase in mean haemoglobin from baseline in the group receiving hydroxyurea plus l‐carnitine, but no changes in the hydroxyurea alone group. However, the study did not directly compare the two groups (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> </section> <section id="CD013767-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD013767-sec-0115"> <h6 class="title">1. Foetal haemoglobin</h6> <p>Neither study reported HbF.</p> </section> <section id="CD013767-sec-0116"> <h6 class="title">2. Long‐term sequelae of non‐transfusion‐dependent β‐thalassaemia</h6> <p>One study comparing hydroxyurea to hydroxyurea plus l‐carnitine (120 participants) reported pulmonary acceleration time (PAT), which provides a measure of pulmonary hypertension (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). Shorter PAT indicates higher pulmonary pressure (<a href="./references#CD013767-bbs2-0068" title="MalleryJA , GardinJM , KingSW , EyS , HenryWL . Effects of heart rate and pulmonary artery pressure on doppler pulmonary artery acceleration time in experimental acute pulmonary hypertension. Chest1991;100:470-3. [DOI: 10.1378/chest.100.2.470]">Mallery 1991</a>). There was an increase in the PAT mean duration from 110.64 (SD 28.73) ms to 116.66 (SD 24.83) ms for the hydroxyurea plus l‐carnitine group. There were no data for the hydroxyurea alone group. We were unable to contact the authors for further details. </p> </section> <section id="CD013767-sec-0117"> <h6 class="title">3. Quality of life</h6> <p>Neither study reported QoL.</p> </section> <section id="CD013767-sec-0118"> <h6 class="title">4. Adverse outcomes</h6> <p>Two studies reported iron overload as baseline ferritin levels, but not the effect of the intervention on this outcome nor the need for any iron chelation (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <section id="CD013767-sec-0119"> <p><b>a. Iron overload</b></p> <p>Two studies reported iron overload as baseline ferritin levels, but not the effect of the intervention on iron overload (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> </section> <section id="CD013767-sec-0120"> <p><b>b. Need for iron chelation</b></p> <p>Neither study reported need for any iron chelation.</p> </section> <section id="CD013767-sec-0121"> <p><b>c. Adverse drug effects</b></p> <p>Both studies prespecified and reported adverse drug effects (<a href="./full#CD013767-tbl-0002">Table 1</a>). </p> <p>One study reported gastrointestinal events including severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding in the resveratrol alone group and hydroxyurea plus resveratrol group (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). The investigators also reported that some participants experienced headaches and malaise with gastrointestinal symptoms, but did not specify which group of participants experienced these events. None of the participants receiving hydroxyurea alone had adverse events. </p> <p>One study comparing hydroxyurea to hydroxyurea plus l‐carnitine combined reported nausea and vomiting (six participants), headache (one participant) and abdominal discomfort (one participant) without specifying the intervention group (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). The study reported no changes to the biochemical parameters and blood counts. </p> <p>The certainty of evidence for adverse effects was very low (<a href="./full#CD013767-tbl-0005">summary of findings Table 4</a>). We downgraded two levels for risk of bias because of unclear randomisation, allocation concealment and blinding, and two levels for imprecision because findings were based on one small study with little information. </p> <p>We present an overall summary of the prespecified adverse effects, reported adverse effects and adverse effects that were not reported in the included studies in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013767-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013767-sec-0122"></div> <section id="CD013767-sec-0123"> <h3 class="title" id="CD013767-sec-0123">Summary of main results</h3> <p>Our review included seven studies with 291 participants with NTDβT receiving eight different interventions that were relevant to this review (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). The age of the participants eligible for recruitment ranged from two years to 50 years. The actual enrolled participants were aged between two and 49 years. There were four pharmacological and four natural HbF inducers either used alone or in combination with another inducer. The duration of intervention ranged from two months to six months. </p> <p>We are uncertain whether any of the eight HbF inducers in this review has a beneficial effect due to each comparison having only one or two studies, and all the studies were very small. Where we found differences between the intervention groups, these differences were small and may not be clinically meaningful. </p> <section id="CD013767-sec-0124"> <h4 class="title">Single foetal haemoglobin inducer versus usual care or placebo</h4> <p>Neither of the two studies comparing HbF versus placebo reported our first primary outcome, the capability of HbF inducers for reducing the need for blood transfusion by increasing haemoglobin or HbF levels, or both (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). Although the evidence was very low certainty, all the HbF inducers in this comparison (Radix Astragali, CNP and HQK‐1001) may increase both haemoglobin and HbF levels, but more importantly, the data to inform us whether this could result in a reduction in transfusion volume or an increase in transfusion‐free interval was not available. </p> <p>We have no information on long‐term sequelae of NTDβT or QoL.</p> <p>Adverse effects, iron overload and the need for chelation therapy were not reported. Adverse drug effects for HQK‐1001 included upper respiratory tract infection, gastrointestinal symptoms such as abdominal pain and vomiting, dizziness, palpitation and headache. None of the prespecified adverse effects of Radix Astragali and CNP was reported to have occurred. </p> </section> <section id="CD013767-sec-0125"> <h4 class="title">Single foetal haemoglobin inducer at any dose compared with another foetal haemoglobin inducer </h4> <p>We found four studies for this comparison (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>; <a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>; <a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). Two studies assessed the need for transfusion, one comparing thalidomide versus hydroxyurea (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>), and one comparing resveratrol versus hydroxyurea (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). There are very little data on the effects of any interventions on transfusion and, therefore, we are very uncertain whether any intervention is able to reduce transfusion. We do not know the effects of a single HbF inducer compared to another for the outcomes of haemoglobin levels, HbF levels and adverse effects because there was only one study per pair‐wise comparison. </p> <p>We have no information on long‐term sequelae of NTDβT or QoL.</p> </section> <section id="CD013767-sec-0126"> <h4 class="title">A single dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer </h4> <p>Two studies compared HbF inducers given at different doses (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>; <a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <p>We are uncertain whether there is any difference in the need for transfusion for the two doses of hydroxyurea that were compared (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>), and we have no information on the need for transfusion for HQK‐1001 (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). </p> <p>The studies assessed different doses, but there is insufficient information to determine whether there are any dose‐dependent effects. Haemoglobin and HbF may be higher at 24 weeks in the group receiving hydroxyurea 10 mg/kg/day compared with the hydroxyurea 20 mg/kg/day group. Investigators in the study of HQK‐1001 reported median haemoglobin and HbF levels graphically, but the groups could not be compared. These comparisons were of low‐ to very low‐certainty evidence. </p> <p>The study that prespecified QoL assessment did not report the outcome (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). </p> <p>The adverse effects for each inducer were reported, but we do not know if there is a difference in adverse effects of a single inducer compared with another because there was only one study per pair‐wise comparison with very low‐certainty evidence. </p> </section> <section id="CD013767-sec-0127"> <h4 class="title">Two or more foetal haemoglobin inducers at any dose or duration compared with usual care, placebo or a single foetal haemoglobin inducer </h4> <p>There were no studies that compared two or more HbF inducers with placebo or usual care, but we identified two studies comparing two HbF inducers against a single HbF inducer (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>For the comparison of hydroxyurea plus l‐carnitine versus hydroxyurea alone, participants needing transfusion during the study period were reported but could not be separated from study arms that we had excluded from this review (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>Haemoglobin may be lower in the group receiving hydroxyurea plus resveratrol when compared with hydroxyurea alone or resveratrol alone, but we are uncertain (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>). There was a rise in haemoglobin reported with hydroxyurea plus l‐carnitine but not with hydroxyurea alone (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>We have no information on HbF or QoL.</p> <p>The adverse effects reported in both studies were mainly related to the gastrointestinal system (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). We do not know if there were differences in adverse effects of each single HbF inducer over another because there was only one study per pair‐wise comparison with very low‐certainty evidence. </p> </section> </section> <section id="CD013767-sec-0128"> <h3 class="title" id="CD013767-sec-0128">Overall completeness and applicability of evidence</h3> <p>All included studies reported the effect of HbF inducers on haemoglobin and HbF, but we do not have information on their effect on blood transfusion. This is important because of the two primary outcomes in this review, blood transfusion would be a more clinically meaningful outcome and the most important outcome for both patients and policymakers. Both haemoglobin and HbF might be considered surrogate outcomes, since haemoglobin levels are used to determine whether a transfusion is needed. We also have insufficient information on QoL and the long‐term sequelae of chronic anaemia to NTDβT. The durations of the interventions were too short for any of the included comparisons to measure long‐term sequelae. </p> <p>Besides information on long‐term outcomes, we do not know whether the effect of HbF inducers is sustained when they are given for longer times. Observational studies on hydroxyurea suggested outcomes were improved up to 24 months (<a href="./references#CD013767-bbs2-0056" title="ItaliaKY , JijinaFJ , MerchantR , PanjwaniS , NadkarniAH , SawantPM , et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clinica Chimica Acta: International Journal of Clinical Chemistry2009;407(1-2):10-5. [DOI: 10.1016/j.cca.2009.06.019]">Italia 2009</a>), but not beyond (<a href="./references#CD013767-bbs2-0069" title="MancusoA , MaggioA , RendaD , Di MarzoR , RiganoP . Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology2006;133(1):105-6. [PMID: 16512837]">Mancuso 2006</a>; <a href="./references#CD013767-bbs2-0095" title="RiganoP , PecoraroA , CalzolariR , TroiaA , AcutoS , RendaD , et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology2010;151(5):509-15. [PMID: 20955403]">Rigano 2010</a>). </p> <p>We have included one sequential‐dose analysis study, but due to the lack of analysable data, we were unable to draw any conclusions from this. There was also a lack of justification for the choice of washout period in the study (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). For any study that is designed to continue at another dose such as cross‐over study or sequential dose‐escalation study, we need to avoid a carryover effect; therefore, not only do we need to know the half‐life of the substance but, more importantly, we need to determine the duration of the clinical effects of the HbF inducer on the target sites such as the bone marrow or erythrocytes. The half‐life of HQK‐1001 was between nine and 15 hours (<a href="./references#CD013767-bbs2-0088" title="PerrineSP , WarginWA , BoosalisMS , WallisWJ , CaseS , KeeferJR , et al. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. Journal of Clinical Pharmacology2011;51(8):1186-94. [PMID: 21422239]">Perrine 2011</a>), but the duration of its clinical effects on target sites, presumably the erythrocytes, is unknown and likely to be much longer. The duration of clinical effects might depend on the duration of RBC survival and this might vary between different types of NTDβT as well as the predominance of HbF, and therefore could vary considerably between individuals. In people with HbE/β‐thalassaemia, RBC lifespan was reduced when compared with a healthy population (<a href="./references#CD013767-bbs2-0106" title="SingerST , KuypersFA , OlivieriNF , WeatherallDJ , MignaccaR , CoatesTD , et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. British Journal of Haematology2005;131(3):378-88. [PMID: 16225658]">Singer 2005b</a>). Similarly, RBCs with predominant HbF had a shorter lifespan than healthy RBCs with HbA<sub>1</sub> predominance (<a href="./references#CD013767-bbs2-0085" title="PearsonHA . Life-span of the fetal red blood cell. Journal of Pediatrics1967;70(2):166-71. [DOI: 10.1016/s0022-3476(67)80410-4]">Pearson 1967</a>). The washout period might also be dependent on whether the person has had their spleen removed. Thus, predetermining the most appropriate washout period could be difficult. </p> <p>RBC lifespan could also be affected by splenectomy (<a href="./references#CD013767-bbs2-0076" title="MusallamKM , RivellaS , VichinskyE , RachmilewitzAE . Non-transfusion-dependent thalassemias. Haematologica2013;98(6):833-44. [DOI: 10.3324/haematol.2012.066845]">Musallam 2013b</a>; <a href="./references#CD013767-bbs2-0102" title="SharmaA , Easow MathewM , PuriL . Splenectomy for people with thalassaemia major or intermedia. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD010517. [DOI: 10.1002/14651858.CD010517.pub3]">Sharma 2019</a>). Only three of the included studies considered the possibility of splenectomised participants responding differently (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>; <a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>; <a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>). </p> <p>The five studies listed in the <a href="./references#CD013767-bbs1-0003" title="">Studies awaiting classification</a> table have 275 participants (<a href="./references#CD013767-bbs2-0020" title="NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020). ">NCT04411082</a>; <a href="./references#CD013767-bbs2-0017" title="ChengYL , ZhangXH , SunYW , WangWJ , HuangJ , ChuNL , et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine2019;25(7):490-6. [PMID: 29761313]NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012). ">Cheng 2019</a>; <a href="./references#CD013767-bbs2-0018" title="HuangL , YaoHX . Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2016;24(3):806-9. [PMID: 27342514]">Huang 2016</a>; <a href="./references#CD013767-bbs2-0019" title="JainM , ChakrabartiP , DolaiTK , GhoshP , MandalPK , BaulSN , et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules &amp; Diseases2021;88:102544. [PMID: 33610115]">Jain 2021</a>; <a href="./references#CD013767-bbs2-0021" title="WuZK , LiuYM , ZhangXH , LiuWJ , LiM , WangRX . Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine)2007;5(2):137-40. [PMID: 17352867]">Wu 2007</a>). Since the included studies had only 291 participants, the inability at this present time to include these 275 potential participants, who represent a comparatively large cohort compared with the included participants, may affect the conclusions of the review. It might also potentially result in the inclusion of information from RCTs on another HbF inducer not currently described in this review. One of our included studies was not published in English and was translated by more than one person to avoid any misinterpretation of data or missing any important information (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </section> <section id="CD013767-sec-0129"> <h3 class="title" id="CD013767-sec-0129">Quality of the evidence</h3> <p>Using the GRADE assessment tool, the overall certainty of evidence for our primary outcomes ranged from low to very low for all comparisons (<a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013767-tbl-0003">summary of findings Table 2</a>; <a href="./full#CD013767-tbl-0004">summary of findings Table 3</a>; <a href="./full#CD013767-tbl-0005">summary of findings Table 4</a>). The main reasons for downgrading the evidence were for risk of bias, indirectness and imprecision. We had concerns about the risk of bias, mainly due to lack or poor descriptions of randomisation and blinding, and selective reporting. </p> <p>We downgraded all outcomes for imprecision because the number of participants was small, the optimal information size was not met and the CIs were very wide incorporating both a substantial benefit and substantial harm. In addition, we downgraded some outcomes for indirectness because the study period was too short to observe any substantial changes or long‐term sequelae of the condition or long‐term adverse effects such as iron overload or need for chelation. </p> </section> <section id="CD013767-sec-0130"> <h3 class="title" id="CD013767-sec-0130">Potential biases in the review process</h3> <p>A potential bias in the review process was our decision to include one sequential dose‐escalation study, in spite of uncertainties about the duration of washout period and the possibility of carry‐over effects (<a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a>). We included this study because it met our inclusion criteria for participants and interventions and also reported our primary outcome. We could not perform a sensitivity analysis to test this decision because there was only one study for comparison. However, we noted from the data given in the study that haemoglobin levels did not appear to return to baseline during the washout period. </p> <p>We reported outcomes that were expressed differently to our prespecified outcomes, for example, rather than reporting our primary outcome (volume of blood transfusion per participant per year), three studies reported the number of participants who required a transfusion during the study period. One study reported pulmonary hypertension measurements as long‐term sequelae of NTDβT. Although we had included this in the background section of the protocol (<a href="./references#CD013767-bbs2-0126" title="FoongWC , HoJJ , LohCK , ViprakasitV . Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD011579. [DOI: 10.1002/14651858.CD011579]">Foong 2015</a>), we had not listed it in our outcomes; we have added it post hoc. </p> <p>We had to make judgements about whether an intervention could be an HbF inducer rather than a form of gene therapy based on the current knowledge of their mechanism of action. Nevertheless, this may change as more information becomes available on the mechanism of action of the included interventions. </p> <p>It is always possible that relevant unpublished data may have been missed. We were made aware of some Chinese language databases (CNKI, VIP, Wan Fang, SinoMed) that we had not searched and which may potentially have contained relevant studies. However, surveying these databases, except SinoMed, revealed that few if any studies in the database were RCTs, and most studies reported outcomes reflecting the Traditional Chinese Medicine concepts of Yin and Yang rather than the type of measurable clinical outcomes we prespecified in this review. We made a judgement that the potential low yield from these databases did not justify searching them systematically. Those studies that we did identify in the Chinese language were not obtained from any of these databases, and they reported both clinical outcomes and outcomes related to Traditional Chinese Medicine practices. </p> </section> <section id="CD013767-sec-0131"> <h3 class="title" id="CD013767-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>Hydroxyurea remains the most commonly studied HbF inducer. The previous version of this review, which only included hydroxyurea as the HbF inducer, found no RCTs comparing hydroxyurea with placebo or usual care (<a href="./references#CD013767-bbs2-0127" title="FoongWC , HoJJ , LohCK , ViprakasitV . Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD011579. [DOI: 10.1002/14651858.CD011579.pub2]">Foong 2016</a>). The only included RCT in that review was the comparison between two different doses of hydroxyurea that has also been included in the current version of this review (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>). However, we are aware of several observational studies assessing responses with various doses of hydroxyurea, from 8 mg/kg/day up to 30 mg/kg/day (<a href="./references#CD013767-bbs2-0024" title="AmoozgarH , FarhaniN , KhodadadiN , KarimiM , CherikiS . Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. European Journal of Haematology2011;87(1):61-7. [PMID: 21447009]">Amoozgar 2011</a>; <a href="./references#CD013767-bbs2-0043" title="El-BeshlawyA , El-GhamrawyM , EL-ElaMA , SaidF , AdolfS , Abdel-RazekAR , et al. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt. Annals of Hematology2014;93(12):2045-50. [PMID: 25062719]">El‐Beshlawy 2014</a>; <a href="./references#CD013767-bbs2-0048" title="FucharoenS , SiritanaratkulN , WinichagoonP , ChowthawornJ , SiriboonW , MuangsupW , et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood1996;87(3):887-92. [PMID: 8562958]">Fucharoen 1996</a>; <a href="./references#CD013767-bbs2-0058" title="KarimiM , CohanN , MousavizadehK , FalahiMJ , HaghpanahS . Adverse effects of hydroxyurea in β-thalassaemia intermedia patients: 10 years' experience. Pediatric Hematology and Oncology2010;27(3):205-11. [DOI: 10.3109/08880011003639952]">Karimi 2010b</a>). These studies have reported similar bone marrow suppression, hepatotoxicity and gastrointestinal symptoms as found in the included study (<a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a>), and also at the higher doses of hydroxyurea (<a href="./references#CD013767-bbs2-0043" title="El-BeshlawyA , El-GhamrawyM , EL-ElaMA , SaidF , AdolfS , Abdel-RazekAR , et al. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt. Annals of Hematology2014;93(12):2045-50. [PMID: 25062719]">El‐Beshlawy 2014</a>; <a href="./references#CD013767-bbs2-0058" title="KarimiM , CohanN , MousavizadehK , FalahiMJ , HaghpanahS . Adverse effects of hydroxyurea in β-thalassaemia intermedia patients: 10 years' experience. Pediatric Hematology and Oncology2010;27(3):205-11. [DOI: 10.3109/08880011003639952]">Karimi 2010b</a>; <a href="./references#CD013767-bbs2-0110" title="TaherAT , MusallamKM , KarimiM , El-BeshlawyA , BelhoulK , DaarS , et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood2010;115(10):1886-92. [PMID: 20032507]">Taher 2010</a>). </p> <p>There are two other Cochrane Reviews that have reported the effectiveness of hydroxyurea in reducing blood transfusion, in SCD (<a href="./references#CD013767-bbs2-0091" title="Rankine-MullingsAE , NevittSJ . Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD002202. [DOI: 10.1002/14651858.CD002202.pub3]">Rankine‐Mullings 2022</a>) and in TDT (<a href="./references#CD013767-bbs2-0025" title="AnsariSH , LassiZS , KhowajaSM , AdilS , ShamsiTS . Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD012064. [DOI: 10.1002/14651858.CD012064.pub2]">Ansari 2019</a>). There were no studies included in the TDT review (<a href="./references#CD013767-bbs2-0025" title="AnsariSH , LassiZS , KhowajaSM , AdilS , ShamsiTS . Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD012064. [DOI: 10.1002/14651858.CD012064.pub2]">Ansari 2019</a>). Besides finding improvements related to SCD, the authors of the SCD review found moderate‐certainty evidence for an improvement in HbF and provide further data on adverse effects (<a href="./references#CD013767-bbs2-0091" title="Rankine-MullingsAE , NevittSJ . Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews2022, Issue 9. Art. No: CD002202. [DOI: 10.1002/14651858.CD002202.pub3]">Rankine‐Mullings 2022</a>). As for NTDβT, there is one systematic review on hydroxyurea for NTDβT which meta‐analysed 11 studies with 859 participants (<a href="./references#CD013767-bbs2-0023" title="AlgiraigriAH , WrightNA , PaolucciEO , KassamA . Hydroxyurea for non transfusion-dependent β-thalassemia: a systematic review and meta-analysis. Hematology/Oncology and Stem Cell Therapy2017;10(3):116-25. [DOI: 10.1016/j.hemonc.2017.02.002]">Algiraigri 2017</a>). The review included studies which were of a pre‐ and postdesign, but there were no RCTs. The authors of that review described serious limitations to the quality of the studies, which limited their conclusions about the efficacy and safety of hydroxyurea. </p> <p>We found no systematic reviews that specifically reviewed trials on HbF inducers for NTDβT. However, there are several narrative reviews that suggested other natural or pharmacological products that might ameliorate anaemia. It is possible that some of these might work by increasing HbF levels. There are several other compounds which are currently being investigated as HbF inducers (rapamycin, angelicin, linear psoralens, ethanol extract, mithramycine, cucurbitacin‐D, fructus <i>Trichosanthis</i>, citropten, bergapten, 5‐azacytidine, trichostatin‐A and short‐chain fatty acids derivatives) but to date, there are no RCTs of these interventions (<a href="./references#CD013767-bbs2-0028" title="BianchiN , ZuccatoC , LamprontiI , BorgattiM , GambariR . Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evidence-Based Complementary and Alternative Medicine: eCAM2009;6(2):141-51. [DOI: 10.1093/ecam/nem139]">Bianchi 2009</a>; <a href="./references#CD013767-bbs2-0046" title="FardAD , HosseiniSA , ShahjahaniM , SalariF , JasebK . Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. International Journal of Hematology, Oncology and Stem Cell Research2013;7(3):47-54.">Fard 2013</a>; <a href="./references#CD013767-bbs2-0063" title="KumariS , MishraA , TiwariA . Beta-thalassemia treatment passing through natural fetal hemoglobin inducers. Journal of Pharmacy Research2011;4(9):3851-5.">Kumari 2011</a>; <a href="./references#CD013767-bbs2-0075" title="MusallamKM , TaherAT , CappelliniMD , SankaranVG . Clinical experience with fetal hemoglobin induction therapy in patients with b-thalassemia. Blood2013;121(12):2199-212.">Musallam 2013a</a>; <a href="./references#CD013767-bbs2-0078" title="NgNY , KoCH . Natural remedies for the treatment of beta-thalassemia and sickle cell anemia-current status and perspectives in fetal hemoglobin reactivation. International Scholarly Research Notices2014;2014:123257. [PMID: 27350962]">Ng 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013767-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013767-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013767-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013767-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 1: Mean haemoglobin (g/dL) at 3 months postintervention, subgroup by types of HbF inducer" data-id="CD013767-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 1: Mean haemoglobin (g/dL) at 3 months postintervention, subgroup by types of HbF inducer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 2: Mean HbF (%) at 3 months, subgroup by types of HbF inducer" data-id="CD013767-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 2: Mean HbF (%) at 3 months, subgroup by types of HbF inducer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 1: Mean haemoglobin (g/dL), subgroup by types of HbF inducer" data-id="CD013767-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 1: Mean haemoglobin (g/dL), subgroup by types of HbF inducer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 2: Mean HbF (%), subgroup by type of HbF inducer" data-id="CD013767-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 2: Mean HbF (%), subgroup by type of HbF inducer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 1: Mean haemoglobin (g/dL)" data-id="CD013767-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 1: Mean haemoglobin (g/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 2: Mean HbF (%)" data-id="CD013767-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 2: Mean HbF (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 3: Major adverse effects (at 24 weeks)" data-id="CD013767-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 3: Major adverse effects (at 24 weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013767-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/urn:x-wiley:14651858:media:CD013767:CD013767-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer, Outcome 1: Mean haemoglobin (g/dL) at 6 months postintervention, subgroup by types of HbF inducer" data-id="CD013767-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_t/tCD013767-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer, Outcome 1: Mean haemoglobin (g/dL) at 6 months postintervention, subgroup by types of HbF inducer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/media/CDSR/CD013767/image_n/nCD013767-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013767-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with usual care or placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Single HbF inducer at any dose or duration compared with usual care or placebo for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in Thailand, Lebanon and China<br/><b>Intervention:</b> single HbF inducer <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or usual care</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level (g/dL) at 3 months was <b>7.3 (SD 1.1) g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.33 g/dL higher</b><br/>(0.54 higher to 2.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT, 2 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The meta‐analysis include Radix Astragali and CNP, but not HQK‐1001. For HQK‐1001, there was no difference in median haemoglobin for any of the 4 doses compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF (%)</b> </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF level (%) at 3 months was <b>54% (SD 17%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 12% higher</b><br/>(−0.74% lower to 24.75% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35<br/>(1 RCT, 2 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The meta‐analysis include Radix Astragali and CNP, but not HQK‐1001.</p> <p>Of the 4 different doses of HQK‐1001 (21 participants), there was an increase in median HbF only with the 20 mg/kg dose when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 2–3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>HQK‐1001 </p> <p>The reported adverse events for each dose of HQK‐1001 were URTI, headache, fever, fatigue, nausea, dizziness, palpitations, suprapubic pain, gastritis, gastroenteritis and severe URTI. The 20 mg/kg/day dose was reported as the dose with the least adverse events – on this dose, 2/9 participants reported URTI, 3/9 reported headache, 1/9 reported suprapubic pain, 2/9 reported nausea and 2/9 reported dizziness, and were free from other adverse effects. However, these events were too few to determine whether higher doses were associated with more or fewer adverse effects or whether there were more adverse effects in the HbF inducer or placebo groups. </p> <p>Radix Astragali </p> <p>No adverse events were reported; no deranged blood counts (white blood cells, neutrophils, platelets), liver (GGT, ALT, AST) and renal (BUN, creatinine) blood profiles. </p> <p>CNP </p> <p>No adverse events were reported; no deranged blood counts (white blood cells, neutrophils, platelets), liver (GGT, ALT, AST) and renal (BUN, creatinine) blood profiles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/>(2 RCTs, 3 interventions) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a, b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ALT:</b> alanine transaminase; <b>AST:</b> aspartate aminotransferase; <b>BUN:</b> blood urea nitrogen; <b>CI:</b> confidence interval; <b>CNP:</b> combined natural preparation; <b>GGT:</b> gamma‐glutamyl transferase; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation; <b>URTI:</b> upper respiratory tract infection. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for indirectness because the follow‐up duration was short and insufficient to see changes.<br/><sup>b</sup>Downgraded two levels for imprecision because of very small information size well below the optimal information size.<br/><sup>c</sup>Downgraded two levels for imprecision because optimal information size was not achieved and there were wide CIs that included both appreciable benefit and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with usual care or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013767-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of adverse events reported in included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HbF inducer</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects prespecified in study method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse effects reported<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Hydroxyurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation on blood investigation (complete blood count, kidney and liver function tests). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg/day</p> <p> <ol id="CD013767-list-0001"> <li> <p>Severe neutropenia (9/29 participants)</p> </li> <li> <p>Thrombocytopenia (10/29 participants)</p> </li> <li> <p>Raised ALT and AST (5/29 participants)</p> </li> <li> <p>Gastrointestinal adverse effects (9/29 participants)</p> </li> </ol> </p> <p>10 mg/kg/day</p> <p> <ol id="CD013767-list-0002"> <li> <p>Severe neutropenia (1/32 participants)</p> </li> <li> <p>Thrombocytopenia (3/32 participants)</p> </li> <li> <p>Raised ALT and AST (2/32 participants)</p> </li> <li> <p>Gastrointestinal adverse effects (3/32 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation on blood investigation (complete blood count, serum ferritin levels, kidney and liver function tests, and fasting blood sugar), and history and physical examination of any occurrence of adverse events. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding (1/18 participants). </p> <p>Headache and malaise were also reported for some participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation of clinical complaints and physical findings.</p> <p>Biochemical parameters and blood counts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting (6 participants), headache (1 participant) and abdominal discomfort (1 participant) without specification to which group the participants were randomised into. </p> <p>No changes to the biochemical parameters and blood counts.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability and safety.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild gastrointestinal upset (number of participants not reported).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, cytopenia, infection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0003"> <li> <p>Respiratory tract infection (10/15 participants)</p> </li> <li> <p>Neurological (1/15 participants)</p> </li> <li> <p>Fever (2/15 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQK‐1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, coagulation profile, blood counts, urinalysis and ECG.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>URTI</p> <p> <ol id="CD013767-list-0004"> <li> <p>10 mg/kg/day: 5/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 1/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 3/8 participants</p> </li> </ol> </p> <p>Headache</p> <p> <ol id="CD013767-list-0005"> <li> <p>10 mg/kg/day: 5/8 participants</p> </li> <li> <p>20 mg/kg/day: 3/9 participants</p> </li> <li> <p>30 mg/kg/day: 2/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 2/8 participants</p> </li> </ol> </p> <p>Fever</p> <p> <ol id="CD013767-list-0006"> <li> <p>10 mg/kg/day: 3/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 2/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 2/8 participants</p> </li> </ol> </p> <p>Fatigue</p> <p> <ol id="CD013767-list-0007"> <li> <p>10 mg/kg/day: 1/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 4/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> <p>Nausea</p> <p> <ol id="CD013767-list-0008"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Dizziness</p> <p> <ol id="CD013767-list-0009"> <li> <p>10 mg/kg/day: 2/8 participants</p> </li> <li> <p>20 mg/kg/day: 2/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 1/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Palpitations</p> <p> <ol id="CD013767-list-0010"> <li> <p>10 mg/kg/day: 1/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Suprapubic pain</p> <p> <ol id="CD013767-list-0011"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 1/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Gastritis</p> <p> <ol id="CD013767-list-0012"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 1/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 0/8 participants</p> </li> </ol> </p> <p>Gastroenteritis</p> <p> <ol id="CD013767-list-0013"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> <p>Severe URTI</p> <p> <ol id="CD013767-list-0014"> <li> <p>10 mg/kg/day: 0/8 participants</p> </li> <li> <p>20 mg/kg/day: 0/9 participants</p> </li> <li> <p>30 mg/kg/day: 0/6 participants</p> </li> <li> <p>40 mg/kg/day: 0/9 participants</p> </li> <li> <p>placebo: 1/8 participants</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thalidomide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tolerability and safety.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence and headache</p> <p>Number of participants with events not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biochemical parameters, cytopenia, infection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0015"> <li> <p>Respiratory tract infection (2/15 participants)</p> </li> <li> <p>Neurological (0/15 participants)</p> </li> <li> <p>Fever (0/15 participants)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali (黄芪) in a tea bag</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood counts (WBC, neutrophils, platelets), liver function (GGT, AST, ALT), renal profile (BUN, creatinine). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None occurred.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CNP in a tea bag.</p> <p>CNP: combination of Radix Astragali (黄芪), <i>Codonopsis pilosula</i> (党参) and tortoise plastron (龟板) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Evaluation on blood investigation (complete blood count, serum ferritin levels, kidney and liver function tests, and fasting blood sugar), and history and physical examination of any occurrence of adverse events. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea and gastrointestinal bleeding (5/16 participants). </p> <p>Headache and malaise were also reported for some of the participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea plus resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding (5/20 participants) </p> <p>Headache and malaise were also reported for some of the participants who had gastrointestinal symptoms (no specification to which group the participants were randomised into). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea plus l‐carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluation of clinical complaints and physical findings.</p> <p>Biochemical parameters and blood counts.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea and vomiting (6 participants), headache (1 participant) and abdominal discomfort (1 participant) without specification to which group the participants were randomised into. </p> <p>No changes to the biochemical parameters and blood counts.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>'None occurred' means that adverse effects were specifically looked for, but none were identified.<br/>ALT: alanine transaminase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CNP: combination natural preparation; ECG: electrocardiogram; GGT: gamma‐glutamyl transferase; URTI: upper respiratory tract infection; WBC: white blood cell count. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of adverse events reported in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013767-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with another foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Single HbF inducer at any dose or duration compared with another HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in Iran, India and China<br/><b>Intervention:</b> single HbF inducer <br/><b>Comparison:</b> another single HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with single HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with another single HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> (transfused volume/year) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>None of the studies reported this outcome using the scale transfused volume/year.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 study reported frequency of transfusion (30 participants, 15 per arm) as mean number of units of blood/participant/year. SDs were not reported. The hydroxyurea group needed a mean of 3 units/participant/year of blood volume (range 1 to 6), while 0 participants in the thalidomide group needed any units of blood. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Hydroxyurea lowered mean haemoglobin compared to resveratrol by MD 0.30 g/dL (95% CI −1.14 to 0.54). </p> <p>Radix Astragali lowered mean haemoglobin compared to CNP by MD 0.50 g/dL (95% CI −1.38 to 0.38). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (4 RCTs, 4 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013767-list-0016"> <li> <p>Comparisons include: hydroxyurea vs resveratrol; hydroxyurea vs thalidomide; hydroxyurea vs decitabine; and Radix Astragali vs CNP. </p> </li> </ol> </p> <p>The study comparing hydroxyurea vs thalidomide did not report this outcome and the study comparing hydroxyurea vs decitabine reported this outcome as peak median haemoglobin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF</b> (%) </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between thalidomide and hydroxyurea, MD 3.50% (95% CI −1.41% to 8.41%). </p> <p>Radix Astragali increased the mean HbF levels compared to natural combination preparation by 5.00% (95% CI −11.44% to 21.44%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (3 RCTs, 3 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparisons include hydroxyurea vs thalidomide; hydroxyurea vs decitabine; and Radix Astragali vs CNP. </p> <p>The study comparing hydroxyurea vs decitabine reported this outcome but did not provide sufficient information to compare the 2 groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 3–6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Hydroxyurea </p> <p> <ol id="CD013767-list-0017"> <li> <p>mild gastrointestinal upset (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>) </p> </li> <li> <p>respiratory tract infection (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> <li> <p>neurological problems (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> <li> <p>fever (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> </ol> </p> <p>Thalidomide </p> <p> <ol id="CD013767-list-0018"> <li> <p>somnolence and headache (<a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a>) </p> </li> </ol> </p> <p>Decitabine </p> <p> <ol id="CD013767-list-0019"> <li> <p>respiratory tract infection (<a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a>) </p> </li> </ol> </p> <p>Resveratrol </p> <p> <ol id="CD013767-list-0020"> <li> <p>gastrointestinal events included severe nausea, vomiting, abdominal pain, diarrhoea and gastrointestinal bleeding, headache and malaise (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>) </p> </li> </ol> </p> <p>Radix Astragali </p> <p>None of the prespecified adverse drug effects (abnormalities to blood counts, liver enzymes levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> <p>CNP </p> <p>None of the prespecified adverse drug effects (abnormalities to blood counts, liver enzymes levels and renal profile) occurred (<a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (4 RCTs, 4 pair‐wise intervention comparisons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c, d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CNP:</b> combined natural preparation; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision because data from only one small trial and the CIs included both appreciable benefit and appreciable harm.<br/><sup>b</sup>Downgraded two levels for imprecision because data were based on one small trial with very wide CIs.<br/><sup>c</sup>Downgraded one level for lack of blinding.<br/><sup>d</sup>Downgraded two levels for imprecision, data from only one small study with very small information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Single foetal haemoglobin inducer at any dose or duration compared with another foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013767-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">One dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>One dose or dose regimen of an HbF inducer compared with another dose or dose regimen of the same HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> specialised outpatient clinic in India<br/><b>Intervention:</b> 1 dose of an HbF inducer<br/><b>Comparison:</b> a different dose of the same HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 1 dose (lower) of HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another dose (higher) of HbF inducer</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/ year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported frequency of transfusion.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin</b> (g/dL) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin with 10 mg/kg/day was <b>9.12 (SD 0.70)</b> <b>g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin with 20 mg/kg/day was<b>2.39 g/dL lower</b> (95% CI 2.80 lower to 1.98 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day.</p> <p>Not downgraded for lack of blinding because of outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF (%)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF for 10 mg/kg/day was <b>35.4% (SD 12.3%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbF with 20 mg/kg/day was <b>10.20% lower</b> (95% CI 16.28% lower to 4.12% lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day.</p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/>(2 RCTs, 2 interventions, 6 different doses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study compared hydroxyurea 10 mg/kg/day vs 20 mg/kg/day; 1 study compared 4 doses of HQK‐1001: 10 mg/kg/day; 20 mg/kg/day; 30 mg/kg/day; 40 mg/kg/day (for a summary of these findings at 2 months, see <a href="./full#CD013767-tbl-0001">summary of findings Table 1</a>). </p> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neutropenia</b> </p> <p>(WBC &lt; 1 × 10<sup>3</sup>/μL, ANC &lt; 0.5 × 10<sup>3</sup>/μL) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000 with hydroxyurea 10 mg/kg/day</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>310 per 1000</b> (42 to 1000) with hydroxyurea 20 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9.93</b> (1.34 to 73.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutropenia would influence the decision to continue the intervention but not the decision to transfuse blood. </p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenia</b> </p> <p>(platelet count &lt; 50 × 10<sup>3</sup>/μL) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000 with hydroxyurea 10 mg/kg/day</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>345 per 1000</b> (105 to 1000) with hydroxyurea 20 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.68</b> (1.12 to 12.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia would influence the decision to continue the intervention but not the decision to transfuse blood. </p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ANC:</b> absolute neutrophil count; <b>CI:</b> confidence interval; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>WBC:</b> white blood cell count. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias because of unclear allocation concealment.<br/><sup>b</sup>Downgraded two levels for imprecision because data were based on one small trial with very small information size.<br/><sup>c</sup>Downgraded two levels for imprecision because data were based on one small trial with very wide CIs.<br/><sup>d</sup>Downgraded one level for indirectness because the follow‐up duration was short and insufficient to see changes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">One dose or dose regimen of a foetal haemoglobin inducer compared with another dose or dose regimen of the same foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013767-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Two or more foetal haemoglobin inducers at any dose or duration compared with a usual management protocol, placebo or a single foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Two or more HbF inducers at any dose or duration compared with a usual management protocol, placebo or a single HbF inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with non‐transfusion‐dependent β‐thalassaemia<br/><b>Setting:</b> outpatient clinics in Iran<br/><b>Intervention:</b> combined ≥ 2 HbF inducers </p> <p><b>Comparison:</b> single HbF inducer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single HbF inducer</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ≥ 2 HbF inducers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of transfusion</b> </p> <p>(transfused volume/year)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported frequency of transfusion.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Transfusion‐free interval</b> (days) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported transfusion‐free interval.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin level</b> (g/dL) </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level (g/dL) with a single HbF inducer ranged from <b>8.5 (SD 1.2) g/dL to 8.8 (SD 1.3) g/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean haemoglobin level with ≥ 2 HbF inducers was <b>0.74 g/dL lower</b><br/>(1.45 lower to 0.03 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/>(1 RCT, 3 intervention combinations) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The single HbF inducer here refers to either hydroxyurea or resveratrol alone.</p> <p>Not downgraded for lack of blinding because outcome considered to be objective.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbF levels</b> (%) </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported HbF levels.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Hydroxyurea vs resveratrol vs combined hydroxyurea plus resveratrol (<a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a>) </p> <p> <ol id="CD013767-list-0021"> <li> <p>gastrointestinal events including severe nausea, vomiting, abdominal pain, diarrhoea, and gastrointestinal bleeding </p> </li> <li> <p>headache</p> </li> <li> <p>malaise</p> </li> </ol> </p> <p>Hydroxyurea vs combined hydroxyurea plus l‐carnitine (<a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a>) </p> <p> <ol id="CD013767-list-0022"> <li> <p>nausea and vomiting (6 participants)</p> </li> <li> <p>headache (1 participant)</p> </li> <li> <p>abdominal discomfort (1 participant)</p> </li> <li> <p>no changes to the biochemical parameters and blood counts</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(2 RCTs, 3 pair‐wise comparisons) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> reported adverse events, but data could not be separated from study arms that we had excluded from this review. </p> <p>An overall summary of adverse effects reported in the included studies is provided in <a href="./full#CD013767-tbl-0002">Table 1</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HbF:</b> foetal haemoglobin; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RCT:</b> randomised controlled trial; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision because based on one small trial with very small information size.<br/><sup>b</sup>Downgraded two levels for risk of bias because unclear randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Two or more foetal haemoglobin inducers at any dose or duration compared with a usual management protocol, placebo or a single foetal haemoglobin inducer for reducing blood transfusion in people with non‐transfusion‐dependent β‐thalassaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013767-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies by foetal haemoglobin inducers</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Age at enrolment (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of splenectomised participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dose and duration</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Single HbF inducer at any dose or duration compared with usual care or placebo</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HQK‐1001</p> <p>(oral tablet)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0002" title="FuchareonS , InatiAC , SiritanaratkulN , KoussaS , TaherA , BoosalisMS , et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280]FucharoenS , InatiA , SiritanaratkuN , TheinSL , WarginWC , KoussaS , et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: 23530969]">Fucharoen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 17–45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sequential dose‐escalation</p> <p> <ol id="CD013767-list-0041"> <li> <p>from 10 mg/kg/day then to 30 mg/kg/day</p> </li> <li> <p>from 20 mg/kg/day then to 40 mg/kg/day</p> </li> </ol> </p> <p>56 intervention days with in between 8 weeks intervention‐free period</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali</p> <p>(tea bag – oral drink)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CNP<sup>a</sup> </p> <p>(tea bag – oral drink)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>Single HbF inducer at any dose or duration compared with another HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs decitabine</p> <p>(oral HU<sup>b</sup> vs subcutaneous) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0005" title="JhaK , RayR , BhattacharyyaM . Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology &amp; Blood Transfusion2019;35(1):S52. [CFGD REGISTER: TH203] ">Jha 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily HU<sup>b</sup> </p> <p>Twice a week decitabine</p> <p>(no other details)</p> <p>Duration: 3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs thalidomide</p> <p>(appearance not stated. Both inducers were taken orally)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0004" title="JainM , DeR , JitaniA , ChakrabartiP , MondalPK , BaulS , et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5]">Jain 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 6–45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 10 mg/kg/day</p> <p>Thalidomide: fixed‐dose 50 mg/day</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs resveratrol<sup>c</sup> </p> <p>(HU<sup>b</sup> vs capsule) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radix Astragali vs CNP<sup>a</sup> </p> <p>(both in similar looking tea bag – oral drinks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0007" title="LuZ , QianX , ZhangC , ChenZ , DuG . Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979]LuZM , QianXH , ChenZW , ZhangCH , GuoLS , ChenJ . Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics)2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: 22613104]">Lu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 6.5, SD 3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose: according to age</p> <p>Duration: 3 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>1 dose or dose regimen of an HbF inducer compared with another dose or dose regimen of the same HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea vs hydroxyurea</p> <p>(tablets)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0001" title="BoharaVV , RautL , BardarkheG , PujariG , ChakrabartiP , RayS , et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion2012;28(4):191-256. [CFGD REGISTER: TH143b] BoharaVV , RayS , ChakrabartiP , RaySS , NathUK , ChaudhuriU . Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: 24144212]">Bohara 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 16.68, SD 6.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 mg/kg/day vs 10 mg/kg/day</p> <p>Duration: 6 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>≥ 2 HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined resveratrol<sup>c</sup> and hydroxyurea vs hydroxyurea alone </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined resveratrol and hydroxyurea vs hydroxyurea alone</p> <p>(Resveratrol capsules, HU<sup>b</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0003" title="Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]HaghpanahS , ZareiT , EshghiP , ZekavatO , BordbarM , HoormandM , et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: 29926158]KarimiM , HaghpanahS , ZareiT , EshgiP , BordbarM , ZekavatO . Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] ">Haghpanah 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 18–42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>Resveratrol: 4 capsules daily</p> <p>Duration: 6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined l‐carnitine and hydroxyurea vs hydroxyurea alone</p> <p>(L‐carnitine tablets, hydroxyurea capsules)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013767-bbs2-0006" title="KarimiM , MohammadiF , BehmaneshF , SamaniSM , BorzoueeM , AmoozgarH , et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: 19799627]NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008). ">Karimi 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 4–35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60/120 participants</p> <p>(inclusive of groups on magnesium chloride)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxyurea: 8–12 mg/kg/day</p> <p>L‐carnitine: 50 mg/kg/day</p> <p>Duration: 6 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>CNP (combined natural preparation): combination of Radix Astragali (黄芪), <i>Codonopsis pilosula</i> (党参) and tortoise plastron (龟板).<br/><sup>b</sup>HU: unsure if the hydroxyurea was in the form of a capsule or tablet, but it was taken orally.<br/><sup>c</sup>Resveratrol: came in a form of a capsule that contained micronised trans‐resveratrol 500 mg and piperine 10 mg. Piperine was added to the capsule to increase the oral bioavailability of resveratrol. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies by foetal haemoglobin inducers</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/full#CD013767-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013767-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Single HbF inducer at any dose or duration compared with usual care or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mean haemoglobin (g/dL) at 3 months postintervention, subgroup by types of HbF inducer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.54, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Combined natural preparation (CNP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.44, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Radix Astragali</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.04, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mean HbF (%) at 3 months, subgroup by types of HbF inducer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.00 [‐0.74, 24.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Combined natural preparation (CNP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [‐11.17, 29.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Radix Astragali</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.00 [‐2.44, 30.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Single HbF inducer at any dose or duration compared with usual care or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013767-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Single HbF inducer at any dose or duration compared with another HbF inducer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mean haemoglobin (g/dL), subgroup by types of HbF inducer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Hydroxyurea versus resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.14, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Radix Astragali versus combined natural preparation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.38, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mean HbF (%), subgroup by type of HbF inducer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Thalidomide versus hydroxyurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐1.41, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Radix Astragali versus combined natural preparation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [‐11.44, 21.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Single HbF inducer at any dose or duration compared with another HbF inducer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013767-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mean haemoglobin (g/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.39 [‐2.80, ‐1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mean HbF (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.20 [‐16.28, ‐4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Major adverse effects (at 24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.93 [1.34, 73.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [1.12, 12.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013767-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mean haemoglobin (g/dL) at 6 months postintervention, subgroup by types of HbF inducer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.45, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Hydroxyurea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.58, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Resveratrol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.93, 0.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013767.pub2/references#CD013767-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013767.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013767-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013767-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013767-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013767-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013767-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD013767-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013767-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013767-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013767\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013767\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013767\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013767\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013767\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013767.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013767.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013767.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013767.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013767.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717997705"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013767.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717997709"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013767.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc590f8aaf49c',t:'MTc0MDcxNzk5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 